CURRICULUM VITAE

**NATALIE LUZINA RASGON, M.D., Ph.D.**

***OFFICE ADDRESS:***

401 Quarry Road, Rm. 2368

Stanford, CA 94305-5723

Telephone: (650) 724-6689

Fax: (650) 724-3144

Email: nrasgon@stanford.edu

**MEDICAL**

**CERTIFICATIONS:**

American Board of Psychiatry and Neurology

Certification in Psychiatry, 44798

January 1998 to present

Medical Board of California

Physician and Surgeon Certificate, A052679

December 1993 to present

Board of Obstetrics and Gynecology, U.S.S.R.

Certification in Diagnostic Ultrasound in

Obstetrics and Gynecology, April 1989

Academy of Medical Sciences, U.S.S.R.

Ph.D. in Obstetrics and Gynecology and

Pathological Physiology, March 1989

Academy of Medical Sciences, U.S.S.R.

Certification in Pathological Physiology

December 1987

Central Institute of Postgraduate Medical Education, U.S.S.R.

Certification in Proficiency in Scientific English

November 1987

Board of Obstetrics and Gynecology, U.S.S.R.

Certification in Gynecological Endocrinology

December 1982

Board of Obstetrics and Gynecology, U.S.S.R.

Certification in Obstetrics and Gynecology

June 1981

**PRESENT POSITIONS:**

Director

Stanford Women’s Health Component of the PGSP

Ph.D. Program, Pacific Graduate School of Psychology

August 2009 to present

Director

Faculty Mentoring Program

Department of Psychiatry

Stanford University School of Medicine

March 2009 to present

Director

Center for Neuroscience in Women’s Health

Stanford University School of Medicine

May 2007 to present

Professor

Department of Psychiatry and Behavioral Science

Obstetrics and Gynecology (by courtesy)

Stanford University School of Medicine

May 2006 to present

Adjunct Professor

Department of Psychiatry and Biobehavioral Sciences

UCLA Neuropsychiatric Institute and Hospital

October 2002 to present

**PREVIOUS POSITIONS:**

Associate Dean

Stanford University School of Medicine

Office of Academic Affairs

September 2012 to October 2013

Associate Professor

Department of Psychiatry and Behavioral Sciences

Stanford University School of Medicine

October 2002 to April 2007

Director of the Women’s Wellness Program

Stanford University School of Medicine

January 2005-April 2007

Director of the Behavioral Neuroendocrinology Program

Stanford University School of Medicine

September 2003 to 2007

Associate Professor (by courtesy)

Department of Obstetrics and Gynecology

Stanford University School of Medicine August 2004 to April 2007

Associate Director of the Women’s Wellness Program

Stanford University School of Medicine

October 2002 to December 2004

Director of the Menopause-Related Mood Disorders Program

UCLA Neuropsychiatric Institute and Hospital

January 1998 to September 2002

Assistant ClinicalProfessor

Department of Psychiatry and Biobehavioral Sciences

UCLA Neuropsychiatric Institute and Hospital

July 1997 to September 2002

Medical Director, Partial Hospitalization Program

Cedars-Sinai Medical Center in Los Angeles, CA

April 1997 to July 1997

Assistant Clinical Professor

Department of Obstetrics and Gynecology

UCLA School of Medicine

July 1996 to March 2000

Clinical Instructor

Department of Psychiatry and Biobehavioral Sciences

UCLA School of Medicine

July 1996 to June 1997

Assistant Professor

Department of Obstetrics and Gynecology

Central Institute of Postgraduate Medical Education

Moscow, U.S.S.R.

January 1989 to December 1989

Attending Physician

Department of Gynecology

Central Hospital of Black Sea Shipping Company

Odessa, U.S.S.R.

February 1984 to December 1985

Assistant Clinical Professor

Department of Obstetrics and Gynecology

Odessa Medical Institute

Odessa, U.S.S.R.

January 1983 to December 1984

Attending Physician

Department of Gynecology

Hospital of Physical Medicine

Odessa, U.S.S.R.

July 1981 to January 1984

**EDUCATION:**

**UNDERGRADUATE/GRADUATE**

Doctor of Medicine, Diploma with HighestHonors

Odessa Medical Institute

Odessa, U.S.S.R.

September 1974 to June 1980

**POSTGRADUATE**

Ph.D. in Obstetrics and Gynecology and Pathological Physiology Central Institute of Postgraduate Medical Education

Central Institute of General Pathology and Pathological Physiology

Academy of Medical Sciences

Moscow, U.S.S.R.

December 1985 to December 1988

**INTERNSHIPS**

Psychiatry

Harbor-UCLA Medical Center

Torrance, CA

July 1992 to June 1993

Obstetrics and Gynecology

Nicolaev State Hospital

Nicolaev, U.S.S.R.

August 1980 to June 1981

**RESIDENCY**

Psychiatry

Cedars-Sinai Medical Center

Los Angeles, CA

July 1993 to June 1996,

Chief Resident, July 1994 to June 1995

**FELLOWSHIPS**

NRSA Research Fellow in Neurobiology

UCLA Neuropsychiatric Institute and Hospital

UCLA School of Medicine  July 1995 to June 1996

Janssen Clinical Scholar

Seventh U.S. Psychiatric & Mental Health Congress

January 1994 to December 1994

Fellow in Gynecological Endocrinology

Central Institute of Postgraduate Medical Education

Moscow, U.S.S.R.

September 1982 to December 1982

**HONORS AND AWARDS:**

1. Best Doctors in America-Elected to Database, November 2015
2. Best Doctors in America –Elected to Database, November 2012
3. Stanford Clayman Institute for Gender Research Fellowship, 2011
4. Lila A. Wallis Award, American Medical Women’s Association, 2010.
5. Cambridge Associates, Who’s Who; Best Doctors, 2010.
6. Women Scientist (Endocrine), Best Doctors, 2009
7. 2009-2010 Best Doctors in America, 2009.
8. The Global Directory of Who’s Who, 2007
9. AcademicKeys Who's Who in Medical Sciences Education (WWMSE), 2007
10. International Scientist of the Year, International Biographical Centre of Cambridge, England, 2002
11. Leo G. Rigler, M.D. Award for Academic Achievement, Cedars-Sinai Medical Center, 1995
12. Diploma with Highest Honors, Odessa Medical Institute, 1980
13. First Prize, Student Research Work, Soviet Union Scientific Student Competition, 1978
14. First Prize, Philosophy Division, Ukraine Scientific Student Competition, 1977
15. First Prize, History Division, Soviet Union Scientific Student Competition, 1975

**SOCIETIES:**

1. Society of Neuroscience, 2014 to present; 1999 to 2004
2. *Fellow*, American College of Neuropsychopharmacology, 2012 to present
3. International Society of Bipolar Disorders (ISBD), Executive Board Member,

2011 to present

1. National Association of Professional Women, 2011 to present
2. Women Leaders in Health Sciences and Technology, 2011 to present
3. New York Academy of Sciences, 2011 to present ; 1994 to 2002
4. International Marce Society, 2009 to present
5. The Royal Society of Medicine, Overseas Fellow, 2008 to present
6. The Endocrine Society, 2007 to present
7. Northern California Psychiatric Society, 2002 to present
8. American Association for the Advancement of Science, 2001 to present
9. North American Menopause Society, 2001 to present
10. International Association on Women’s Mental Health, 2001 to present
11. International Society of Psychoneuroendocrinology, 1997 to present
12. *Active Member*, American College of Neuropsychopharmacology, 2006 to 2012
13. *Fellow*, American Psychiatric Association, 2004 to 2012
14. Society of Biological Psychiatry, 2001 to 2013
15. International Society of Psychosomatic Obstetrics and Gynecology, 1994-2000
16. American Medical Association, 1993 to 2003
17. American Psychiatric Association, 1993 to 2012
18. Southern California Psychiatric Society, 1993 to 2002
19. *Vice-President*, Scientific Society of Young Scientists, Central Institute of Postgraduate Medical Education, U.S.S.R., 1986 to 1989
20. Society of Pathological Physiology, U.S.S.R., 1985 to 1990
21. Society of Obstetrics and Gynecology, U.S.S.R., 1983 to 1990
22. Society of Physical Medicine, U.S.S.R., 1982 to 1989
23. *President*, Scientific Society of Young Scientists, Pirogov Medical Institute, U.S.S.R., 1975 to 1980

**COMMUNITY INVOLVEMENT:**

1. Alley to the Valley- Networking for Silicon Valley Women , 2011 to 2013
2. 85 Broads- Global Networking – 2010 to 2013

**NATIONAL AND INTERNATIONAL COMMITTEES:**

1. Society for Women’s Health Research Science Committee, 2016 - present
2. Alzheimer’s Disease-Related Dementias Summit Satellite Meeting: Metabolic and Vascular Contributions to Neurocognitive Dysfunction, National Institutes of Health (NIH), April 2016
3. *Member*, Interdisciplinary Network on Sex and Gender Differences in Alzheimer’s Disease
4. *Co-Chair*, American College of Neuropsychopharmacology Liaison Committee
5. *Member*, Anthem Behavioral Health Subcommittee, 2015-present
6. *National Advisory Board Member*, Anthem Behavioral Health Subcommittee, 2015-present
7. *Member*, American Diabetes Association -Research Grant Review Committee, 2013-present
8. *Member*, Advisor: Scientific American, 1,000 Scientists in 1,000 Days, 2011-present
9. *Member*, Scholar Universe Neuroscience, 2010-present
10. *Reviewer*, Research and Development Excellence funding, Kentucky Science & Engineering Foundation, 2010-present
11. *Member,* Women in Endocrinology, 2010-present
12. *Member*, Teaching and Mentorship Committee, ACNP, 2009 - present
13. George N. Thompson Award Committee, Society of Biological Psychiatry, 2009 – present
14. Task Group Member, Stanford University Mood Disorder Center, National Network of
15. Depression Centers Women and Mood Disorders Task Group, November 2009-present
16. Advisory Board Member, International Society for Bipolar Disorder on Women’s Health (ISBD), 2009-present
17. Member, Nominating Committee: Nobelkommitten for fysiologi eller medicin, 2007- present
18. Section Head, “Psychological Problems in Women of Reproductive Age,” and “Psychological Challenges & Issues for Women,” Women's Health Faculty, Faculty of 1000 Medicine, 2004-present
19. Scholar Universe Neuroscience, 2004 to present
20. *Chair*, Special Emphasis Panel on AD, National Institute of Health, 2010-2015
21. External Examiner, Doctoral Program, Department of Neurology And Neurosurgery, McGill University, 2007-2015
22. *Chair*, Adult Psychopathology and Disorders of Aging (APDA) Study section, CSR, NIH 2009-2014
23. Member, Human Subjects Research Committee, ACNP, 2009-2012
24. Member, Education Committee, ACNP, 2009-2011
25. *Advisor*, DSM-V Task Force, Bipolar Disorder Section, Dec 2008-2010
26. Bipolar Statistical Summit: Methodologies to Advance Long Term Intervention Trials, National Institute of Health (NIH), October 2008
27. Nominating Committee, Society of Biological Psychiatry, 2008- 2011
28. *Chartered Member*, NIH Center for Scientific Review Group, Adult Psychopathology and Disorders of Aging (APDA), February 2008-2014
29. West Coast Work Group, National Institute of Health (NIH) Estrogen and Cognitive Aging Work Group, Jan 2008
30. The Science Advisory Board, May 2006-May 2008
31. NIMH Services Research Review Committee, June 2005
32. NIH eRA Commons Special Emphasis Panel and Scientific Review Group, May 2005
33. *Committee Member*, National Institute on Aging Workshop, “Bench to Bedside: Estrogen as a Case Study,” 2004
34. Council of Healthcare Advisors, Gerson Lehrman Group, 2004 to 2007
35. Planning Committee on Management of Menopause-Related Symptoms, National Institutes of Health, 2004
36. Committee on Endocrine, Metabolic and Reproductive Issues in Neurology and Psychiatry, The Endocrine Society, 2004
37. The Expert Consensus Consortium, Health Knowledge Improvement Foundation, 1999
38. *Scientific Secretary*, Gynecological Subcommittee, Pharmacological Committee, Ministry of Health, U.S.S.R., 1987 to 1990
39. *Vice* *President*, National Committee of Biochemistry, U.S.S.R., 1985 to 1990

**UNIVERSITY COMMITTEES:**

1. Stanford Neurosciences Institute, Affiliated Faculty Member, 2013-present
2. Member, Stanford Physician Wellness Committee, 2010-2014
3. *Director,* Department of Psychiatry and Behavioral Sciences Faculty Mentoring Program, 2009-2011
4. A&P, School of Medicine, Stanford University, 2009-2012
5. Faculty Mentor, Women and Medicine Mentorship Program, School of Medicine, Stanford University, 2009-present
6. Faculty Affiliate, Center for Aging, 2008- present
7. *Chair*, Medical School Faculty Senate, Stanford University, 2009-2012
8. Mentor, Intensive Course in Clinical Research (ICCR), Stanford University, 2008-present
9. Mentor, Career Development Institute, 2007-present
10. Committee on Performance, Professionalism and Promotion (CP3), Stanford University, 2008-2012
11. Senate Steering Committee, Stanford University, 2008-2012
12. Multidisciplinary Advisory Committee, General Clinical Research Center, Stanford Hospital, 2006-present
13. Faculty Affiliate, Michele Clayman Institute on Gender, 2006-present
14. Departmental Senator, Stanford School of Medicine, 2006-2009
15. *Co*-*Chair*, Faculty Women’s Forum, Stanford University, 2005-present
16. Advisory Board on Women’s Health, Stanford University, 2004-present
17. The Stanford Primary Care Associate Program, 2004-2007
18. Women's Cardiovascular Health Committee, Stanford Cardiovascular Institute, 2004-2008
19. Alternate Senator, Stanford School of Medicine, 2004-2006
20. Administrative Panel on Human Subjects in Medical Research, Stanford University, 2004- 2005
21. Career Development Center, Stanford University, 2003-2006
22. Medical student mentor, Faculty-Student Partnership Program, 2003-present
23. Medical School Admissions Panel, Stanford University, 2003-2005
24. *Chair*, Women’s Wellness Seminars Program, Stanford University, 2003-2014

**VISITING PROFESSOR:**

1. Erasmus MC, Rotterdam, The Netherlands, 2016
2. Makati Medical Center, Makati City, Philippines, 2011
3. Istanbul, Turkey 2010
4. University of Cincinnati, 2010
5. Fudan University, Shanghai, China, 2009
6. University of Arizona, Phoenix, Arizona, 2007
7. University of Vermont, College of Medicine, Burlington, Vermont, 2004
8. Karolinska University , Stockholm, Sweden, 2002

**PAST ADVISORY BOARDS & COMMITTEES:**

1. Advisory Board meeting on Bipolar Disorder, Eli Lilly and Company, 2003
2. Advisory Board meeting on Women’s Issues, Abbott Laboratories, 2003
3. Special Issues Board on Women’s Issues, Wyeth-Ayerst Pharmaceuticals, 2003, 2008
4. *Chair*, Search Committee for the Elizabeth Blackwell Award, UCLA School of Medicine, 1999 to 2003
5. Search Committee for the Norman Cousins Psychoneuroimmunology Chair, UCLA School of Medicine, 1998
6. UCLA Liver Transplant Committee, UCLA School of Medicine, 1997 to 2002
7. UCLA General Clinical Research Center Medical Advisory Committee, UCLA School of Medicine, 1996 to 2002
8. International Medical Graduates Committee, Southern California Psychiatric Society, 1993 to 2001

**CONSULTANT FOR:**

1. Sunovion Pharmaceuticals, 2013-present
2. Shire Pharmaceuticals, Neuroscience Medical Strategy, 2013-present
3. National Network of Depression Centers (NNDC) –Women and Mood Disorders Task Group, 2009-Present
4. American Physician Institute for Advanced Professional Studies, CME to Go, 2011- 2015
5. Czech Science Foundation, 2011-2014
6. Takeda Pharmaceuticals, 2011-2014
7. Academic Room, Online Educational Academic Resources, 2012-2013
8. Health Tap, Medical Expert Network, 2012-2013
9. Wyeth Pharmaceuticals, 2008- 2009
10. Abbott Laboratories, Neuroscience Division, 2002-2003

**REVIEWER FOR:**

1. Diabetes Care
2. American Journal of Psychiatry
3. Archives of General Psychiatry
4. Harvard Review of Psychiatry
5. Molecular Psychiatry
6. Neuropsychopharmacology
7. New England Journal of Medicine
8. OMICS Publishing Group – Gynecology & Obstetrics: Current Research
9. Women's Health Research, Institute of Medicine
10. Advances in Therapy's Editorial Board
11. The Open Pharmacology Journal Editorial Board
12. Depression: Mind and Body
13. American Journal of Geriatric Psychiatry
14. American Journal of Primatology
15. Drugs and Aging
16. Fertility and Sterility
17. Journal of Affective Disorders
18. Journal of Clinical Endocrinology and Metabolism
19. Journal of Clinical Psychiatry
20. Journal of Clinical Psychopharmacology
21. Journal of Psychiatry & Neuroscience
22. Neurobiology of Aging
23. NeuroImmunoModulation
24. Obstetrics and Gynecology
25. Pharmacopsychiatry
26. Psychoneuroendocrinology
27. Psychopharmacology
28. Reproductive Biology and Endocrinology
29. Ultrasound, Obstetrics, and Gynecology
30. Acta Psychiatrica Scandinavica

**GRANT REVIEWER FOR:**

1. Ad Hoc Reviewer for Women’s Health Research, Institute on Medicine, 2009-present
2. Department of Neurology And Neurosurgery, McGill University, 2007-present
3. Department of Health Services Alzheimer’s Disease Program, 2007-present
4. Kentucky Science and Engineering Foundation, 2006-present
5. Ad Hoc Reviewer for Alzheimer’s Association, 1999-present
6. Ad Hoc Reviewer for NIMH, Intramural Branch, 1999-present
7. Wellbeing of Women, 2010-2012
8. Michigan Diabetes Research and Training Center, 2005-2008
9. Netherlands Organization for Health Research and Development, 2005-2008
10. KEEPS Ancillary Studies, 2005-2007

**INVITED SERVICE ON EDITORIAL BOARDS:**

* 1. Editorial Board Member, *Bipolar Disorders*, 2016 - present
  2. Senior Editor, Women’s Health, *Current Psychiatry*, 2015- present
  3. Editorial Board Member, *Journal of Affective Disorders*, 2015- present
  4. *Journal of Reproductive Biology and Health*, 2014-present
  5. Guest Editor, *Bipolar Disorders*, 2013
  6. Editorial Board Member, *International Journal of Bipolar Disorders*, 2012-present.
  7. Editorial Board Member, SciTechnol-International Publisher of Science, Technology, and Medicine, OMCIS Group, 2012-present.
  8. Editorial Board Member, Columbia International Publishing, 2012-present
  9. Senior Editor, *American Journal of Neurodegenerative Disease*, 2012-present
  10. Editorial Review Board Member, *American Journal of Alzheimer’s Disease*, 2011-present
  11. Editorial Board Member, *Annals of Clinical Psychiatry*, American Academy of Clinical Psychiatrists (AACP), 2010-present
  12. Editor-in-Chief, *International Journal of Women’s Health*, 2009-present
  13. Editorial Board Member, OMICS Publishing Group – *Gynecology & Obstetrics: Current Research*, 2011-Present
  14. Editorial Board Member, *Current Psychiatry*, 2009-present
  15. Editor, *Journal of Behavioral & Social Science* Issues, 2012-2014
  16. Guest Editor, *Brain Research*, 2009
  17. Editorial Board Member, Open Access *Journal of Contraception*, July 2009
  18. Editorial Board Member, *Advances in Therapy*, October 2008- 2009
  19. Editorial Board Member, *International Psychiatry and Behavioral Neurosciences* (IPBN), July 2007

**TEACHING COURSES AND ACTIVITIES:**

1. *Program Director,* Clinical Neuroscience and Women’s Health Program,

Stanford University School of Medicine in conjunction with Palo Alto University,

2009 to Present

1. *Course Director,* “Clinical Neuroscience in Women’s Health”, Undergraduate Division, Stanford University 2010, 2011
2. *Course Director*, “Clinical Neuroscience in Women’s Health”, Human Biology Undergraduate Division. Stanford University, 2008
3. *Course Director*, “Neuroscience and Psychology of Women’s Health”, Human Biology Undergraduate Division. Stanford University, 2007
4. *Chair*, Physicians' Information and Education Resource (PIER): Update in Bipolar Disorders, 2006.
5. Annual Mentorship Meetings with MD/PhD Students, Stanford School of Medicine, 2005-present.
6. “Madness and the Womb: Mental Illness in Women through the Centuries.” Undergraduate course, Stanford University, 2005-2007
7. “Menopause-HRT Risks/Benefits, Routine Screening Exams, Psychosocial Aspects, and Other Physiological Disorders.” Lecture Series, Primary Care Associate Program, Stanford School of Medicine, 2004
8. Core Psychiatric Clerkship, Stanford School of Medicine, 2003 to 2007
9. Faculty-Student Scholarly Concentration Mentorship, Stanford School of Medicine, 2003 to 2006
10. “Mood and Menopause: Female Specific Mood Disorders.” Undergraduate course, Stanford University, 2003 to 2005
11. “PMDD and Premenstrual Exacerbation of Mood Disorders: How Do We Tell the Difference?” Seminars in Women’s Wellness, Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, 2003
12. “Mood and Menopause: Female Specific Mood Disorders.” Physician Assistant/Nurse Practitioner Course, Stanford School of Medicine, 2003
13. Psychopharmacology Seminar, Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, 2002 to present
14. “The Neuroendocrinology of Mood Disorders.” *Co*-*Chair*, CME Course, Annual Meeting, American Psychiatric Association. New York, NY: May 2002.
15. “New Frontiers in the Neuroendocrinology of Affective Disorders.” *Course* *Director*, Annual Meeting, American Psychiatric Association. Philadelphia, PA: May 2002.
16. “Psychopharmacology of Premenstrual Dysphoric Disorder.” Psychiatry Residency Advanced Psychopharmacology Course, Cedars Sinai Medical Center. Los Angeles, CA: 2002.
17. “Neuroendocrinology in Mood Disorders: Dysregulation and Treatment.” *Course* *Co*-*Director*, Annual Meeting, American Psychiatric Association. Philadelphia, PA: May 2001.
18. Core Curriculum, UCLA School of Medicine, 2001 to 2002
19. Psychiatric Clerkship, UCLA School of Medicine, 2000 to 2002
20. Psychopharmacology, UCLA School of Medicine, 2000 to 2002
21. Obstetrics and Gynecology Core Clerkship, UCLA School of Medicine, 1998 to 1999
22. Seminars on Depression and Anxiety in Women, UCLA School of Medicine, 1998 to 1999
23. Psychopathology, UCLA School of Medicine, 1997 to present
24. “Female-Specific Mental Disorders.” Yearly Grand Rounds, Consultation-Liaison Service, UCLA Neuropsychiatric Institute and Hospital, 1997 to 2002
25. “Selected Topics in Psychiatry for House Staff.” Department of Obstetrics and Gynecology, UCLA Medical Center, 1997 to 1999
26. “Violence against Women.” Lecture for undergraduate course, UC Los Angeles, 1997
27. “Neurobiology of Violence.” Lectures for postgraduate course, UC Los Angeles, 1997
28. “Psychiatry Lectures for Primary Care Specialties.” Didactic Course for House Staff, Cedars-Sinai Medical Center. Los Angeles, CA: 1997.
29. “Eating Disorders.” Seminar, Department of Obstetrics and Gynecology, UCLA Medical Center, 1997
30. “Violence against Women: Psychological Assessment and Management of Rape, Incest and Domestic Violence Victims.” Seminar, Department of Obstetrics and Gynecology, UCLA Medical Center, 1997
31. “Postpartum Depression.” Seminar, Department of Obstetrics and Gynecology, UCLA Medical Center, 1997
32. “Psychopharmacology for Psychotherapists.” Cedars-Sinai Medical Center. Los Angeles, CA: 1994
33. “Menstrual Abnormalities across the Woman’s Life Cycle.” Ambulatory Course, Family Planning Clinic. Moscow, U.S.S.R.: 1988 to 1989.
34. “Diagnostic Ultrasound in Obstetrics and Gynecology.” Course, Central Institute for Postgraduate Medical Education. Moscow, U.S.S.R.: 1989.
35. “Approaches to the Treatment of the Infertile Couple.” Ambulatory Course, Family Planning Clinic. Moscow, U.S.S.R.: 1986 to 1988.
36. “Differential Diagnosis and Management of Dysmenorrhea.” Course, Central Institute for Postgraduate Medical Education. Moscow, U.S.S.R.: 1986 to 1989.
37. “Neuroendocrine Aspects of Dysmenorrhea.” Course, Central Institute for Postgraduate Medical Education. Moscow, U.S.S.R.: 1986 to 1989.

**PRESENTATIONS BY INVITATION AT NATIONAL AND INTERNATIONAL CONFERENCES AND ACADEMIC LECTURES:**

2016 “Insulin Resistance and Telomere Length in Treatment of Depressive Disorders,” (Co-Chair), In “Allostasis Insulin and the Brain: Implications for the Disease Modeling and Treatment in Psychiatry.” Workshop proposal accepted at the 25th European Congress of Psychiatry, Annual Meeting of the European Psychiatric Association, Florence, Italy, April 1-4 2017.

2016 “Insulin Resistance and Markers of Allostatic Load,” (Co-Chair), In “Refining Disease Models in Mood Disorders: Results from the PALS.” Symposium submitted to the 25th European Congress of Psychiatry, Annual Meeting of the European Psychiatric Association, Florence, Italy, April 1-4 2017

2016 “Association of Alzheimer's Disease and Other Cognitive Impairments with Metabolic Syndrome: Whenceforth Causality?” (Co-Chair), Symposium submitted to the annual meeting of the Society for Neuroscience, San Diego, CA, November 12-16.

2016 “Corticotrophin Releasing Factor (CRF) R1 Antagonism as Intervention Targets in Behavioral Disorders: Have We Missed the Coals for the Flames? Is it Time to Refine the Target for Drug Development?” (Co-Chair), Symposium submitted to the annual meeting of the American College of Neuropsychopharmacology, Hollywood, FL, November 12-16.

2016 “Insulin Resistance and Telomere Length in the Treatment of Depressive Disorders, In “Neuroinflammation Mechanisms and Neurodevelopment: Novel Translational Models of Neuropsychiatric Disorders. Symposium submitted to the annual meeting of the American College of Neuropsychopharmacology, Hollywood, FL, November 12-16.

2016 “Publically Funded BRAIN Initiatives from US and EU Perspectives: Will the Brain Yield to the Bucks?” (Study Group Participant). Annual meeting of the American College of Neuropsychopharmacology, Hollywood, FL, November 12-16.

2016 Grand Rounds – University of Miami, Department of Psychiatry & Behavioral Science, Miami, FL, October 2016

2016 Grand Rounds – Erasmus MC, Department of Psychiatry, Rotterdam, The Netherlands, July 2016

2016 “Bipolar Disorder in Women Throughout the Reproductive Life Cycle: A Case- Based Approach and Evidence Based Guidelines” (Chair), Pre-Conference Course accepted at the annual meeting of the International  Society for Bipolar Disorders, Amsterdam, The Netherlands, July 13-16.

2016 “Puberty-specific Presentations of Bipolar Disorder,” Parallel session accepted at the annual meeting of the International Society for Bipolar Disorders, Amsterdam, The Netherlands, July 13-16. 

2016 “Advances in the Treatment of Bipolar Disorder,” Master course presented at the Annual Meeting of the American Psychiatric Association, Atlanta, Georgia, May 14- 18.

2015 “3D Dilemma of this Century” (Plenary Speaker), International Conference on Brain Disorders and Therapeutics, London, England, August 24-26

2015 “From Neuron to Neighborhood: An Update on Contemporary Models for Disease Pathogenesis, Clinical Characterization, and Treatment of Bipolar Disorder” (Chair), annual meeting of the American Psychiatric Association, Toronto, Canada, May 16- 20

2015 “Brain Derived Neurotrophic Factor and Biomarkers of Insulin Resistance in Women with Bipolar Disorder,” In N. Rasgon (Chair), “Neuroprogression and Neuroprotection in Bipolar Disorder,” 24th European Congress of Psychiatry, Annual Meeting of the European Psychiatric Association, Vienna, Austria, March 28-31

2014 “Genetic and Epigenetic Contributions to Reproductive-related Mood Disorders” (Chair), Annual Meeting of the American College of Neuropsychopharmacology, Phoenix, Arizona, December 2014

2014 “Dementia: An Underlying Disease Mechanisms” (Chair), 2nd International Conference on Alzheimer’s Disease and Dementia, Valencia, Spain, September 2014

2014 “Insulin Resistance: Risk Factor for Dementia,” 2nd International Conference on Alzheimer’s Disease and Dementia, Valencia, Spain, September 2014

2014 Annual Meeting of the American Diabetes Association, San Francisco, CA, June 13- 16, 2014

2014 Annual Meeting of the American Psychiatric Association, Symposium, New York, May 2-7, 2014

2014 Rasgon, N. (Chair), Ozerdem, A., & Bauer, M. Neuroendocrine Challenges and Gender Differences in Bipolar Disorder., International Society of Bipolar Disorders, Seoul, South Korea, March 18-21, 2014

2013 Neuroendocrine Correlates of Depression in Pregnancy and Postpartum,” 5th World Congress on Women’s Health, International Association for Women’s Mental Health, Lima, Peru, March 4-7

2013 Grand Rounds – Mt. Sinai School of Medicine, New York

“Disturbances in Insulin Glucose Homeostasis in Disorders of Mood and Cognition”

March 2013

2013 American College of Neuropsychopharamcology, Miami, FL, December 7-11, 2013

2013 Molecular Psychiatry Conference, San Francisco, CA, November 8-10, 2013

2012 Clinical Trials in Alzheimer’s Disease, Monaco, October 2012

2012 Symposium Chair, Marce Society, “Biomarkers and Predictors Outcome of Perinatal Mood Disorders,” Paris, France, September 2012.

2012 Advanced Academy of Neuroscience, “Estrogen Therapy and Cellular Biomarkers of Cellular Aging in Women at Genetic Risk of Alzheimer’s Disease,” Sienna, Italy,

September 2012

2012 The Corporate State Summit: Panelist, “Leadership: Brain Research or Bias?”

Vancouver, British Columbia, Canada, May 2012

2012 The NIH Common Fund, Forward Focus Workshop, San Francisco, California, May 2012

2012 International Society for Bipolar Disorders, 5th Biennial Conference

Istanbul, Turkey, March 2012

2012 Grand Rounds – Santa Clara County Mental Health, “Psychiatry/ Women’s Mental Health Issues and Mood Disorders,” February 2012

2011 Diabetes and the Brain Symposium, “Default Mode Network Abnormalities in Insulin Resistant Postmenopausal Women Receiving Estrogen Therapy,”

Alexandria, Virginia, October 2011

2011 National Institute on Mental Heatlth RDoC Conference on Positive Valence Systems, Washington DC, June 2011

2011 “Metabolic function in patients with Bipolar Disorder,” European Psychiatric Association, Athens, Greece, April 2011

2011 Grand Rounds – MAYO Clinic College of Medicine, February 2011

2010 Grand Rounds – Stanford University School of Medicine – Nuclear Medicine, November 2010

2010 “Default Mode Network Abnormalities in Insulin Resistant Postmenopausal Women with Recurring Estrogen Therapy,”49th Annual Meeting, American College of Neuropsychopharmacology), Miami Beach, Florida

2010 “Neuroendocrine and Neuroimmunological Correlates of Biopolar Disorder in Women” (Chair), 163rd Annual Meeting, American Psychiatric Association, New Orleans, Louisiana

2010 92nd Annual Meeting, The Endocrine Society, San Diego, CA

2010 “Quaffing Quanta of Quality from Quick-Witted Quintessentialists,” Psychiatric Update Conference, University of Wisconsin Medical School, Madison, Wisconsin, November 2010

2010 “Mood and Anxiety Disorders: Solving Clinical Challenges, Improving PatientCare,” Current Psychiatry/American Academy of Clinical Psychiatrists (AACP), Continuing Medical Education Conference, Chicago, Illinois

2010 “Essential Psychopharmacology,” 163rd Annual Meeting, American Psychiatric Association, New Orleans, Louisiana

2010 “Window of Opportunity of Estrogen Therapy for Neuroprotection,” (Chair), International Conference, Stanford University, California

2010 Grand Rounds - Stanford University School of Medicine, Nuclear Medicine

Stanford, California

2010 Grand Rounds - University of California San Francisco, San Francisco, California

2010 Grand Rounds - University of Massachusetts Medical School, Worcester, Massachusetts

2009 “Effects of Estrogen in CNS”, Kline Memorial Lecture, Brain Research Institute, Brain Research Institute, Cincinnati, Ohio.

2009 “Neuroendocrine Correlates of Bipolar Disorder,” Plenary lecture, Turkish National Psychiatry Congress.

2009 “Bipolar Disorder in Women: Clinical and Neuroendocrine Correlates” (Chair), Women’s Mood Disorders, Latino Behavioral Health Initiative, National Institute of Mental Health.

2009 “Neuroendocrinology and Neurobiology of Aging” (Chair), International Society of Psychoneuroendocrinology.

2008 “Estrogen Effects in the Brain,” Annual Psychopharmacology Symposium, Stanford University, California, April 2008.

2008 “Co-morbidities in Patients with Bipolar Disorder.” Grand Rounds, Department of Mental Health Services, Youngstown, Ohio, January.

2007 Insulin Resistance and Cerebral Metabolism in Women at Risk for Alzheimer’s Disease –Chair, Panel session, American College of Neuropsychopharmacology, Boca Raton, Florida, December.

2007 “Women’s Issues in Bipolar Disorder.” Twelfth Annual Psychiatric Update Titus Harris Society 47th Annual Meeting. Galveston, Texas, April.

2007 “Hormones, Cognitive Function and Dementia.” Expert meeting. Loughborough, England, March.

2007 “Evolving Therapeutic Approaches for Bipolar Disorder, Psychotic Illness and

Depression.” Grand Rounds, Loma Linda University, Loma Linda, CA, February.

2007 “Evolving Therapeutic Approaches for Bipolar Disorder, Psychotic Illness and

Depression.” Grand Rounds, University of Arizona, Tucson, AZ, February.

2006 “Metabolic Syndrome with Atypical Antipsychotics: State of the Art.”

“Reproductive and Metabolic Markers in Women with Bipolar Disorder.” 2nd Biennial Conference of the International Society for Bipolar Disorders. Edinburgh, Scotland, August.

2006 “Bipolar Disorder in Women: Clinical and Metabolic Correlates.” Collegium Internationale Neuro-Psychopharmacologicum 25th Biennial Congress. Chicago, IL, July.

2006 “Educational Translational Research in Geriatric Psychiatry: Implications for Symptomatic and Preventative Interventions.” Annual Meeting, National Institute of Mental Health, New Clinical Drug Evaluation Unit. Boca Raton, FL, June.

2006 “Bipolar Disorders in Women: Clinical and Metabolic Correlates” Annual Meeting, American Psychiatric Association. Toronto, Canada, May.

2006 “Medical Co-morbidities of Dementia.” *Chair*, Annual Meeting, American Association for Geriatric Psychiatry. Puerto Rico, March.

2006 “Reproductive Effects of Anticonvulsant Medications” Grand Rounds, University of Illinois at Chicago. Chicago, IL, April.

2005 “Neuroendocrinology of Depression and Alzheimer’s Disease: Insulin Resistance-A Missing Link?” *Co-Chair,* “Cognition and Aging From MCI to Dementia: Neurobiological and Neuroendocrine Correlates” Symposium sponsored by Forest Laboratories, Inc. Newport Beach, CA, October.

2005 “Insulin Resistance: The Link Between Affective Disorders and Alzheimer’s Disease.” *Chair*, “Insulin resistance & Metabolic Syndrome in Neuropsychiatry.” American Psychiatric Association 2005 Institute on Psychiatric Services. San Diego, CA, October.

2005 *Chair*, CME Symposium on Challenges of Diagnosing and Treating Depression and Anxiety in the Obstetrics and Gynecology Setting. Annual Clinical Meeting, American College of Obstetricians and Gynecologists. San Francisco, CA, May.

2005 “Medical and Psychiatric Comorbidities of Dementia.” *Co-Chair*, “Medical and Psychiatric Comorbidities of Dementia” CME Symposium sponsored by Forest Laboratories, Inc. New York, NY, May.

2005 “Bipolar Disorder: Impact of Reproductive Hormones.” Annual Meeting, American Psychiatric Association. Atlanta, GA, May.

2005 “Insulin Resistance: The Link Between Affective Disorders and Alzheimer’s Disease.” *Chair*, “Insulin Resistance and Metabolic Syndrome in Neuropsychiatry” Symposium at the Annual Meeting of the American Psychiatric Association. Atlanta, GA, May.

2005 “Mood Disorders in Women” Grand Rounds, University of Texas Southwestern Dallas. Dallas, TX, November.

2005 “Reproductive Health and Metabolic Correlates in Women with Bipolar Disorder.” Grand Rounds, Mayo Clinic. Rochester, MN, June.

2005 “Latest Advances in the Multidimensional Treatment and Assessment of Bipolar Disorder.” Grand Rounds, St. Louis University. St. Louis, MO, May.

2005 Career Development Institute faculty, Pittsburg, PA, 2005-present

2005 “Reproductive and Hormonal Issues in Women with Bipolar Disorder.” Psychiatric Update: Biopsychiatric Brilliance Bestowed by Brobdingnagian Bellwethers. Madison, WI, March.

2004 “Special Considerations in Bipolar Disorder.” U.S. Psychiatric & Mental Health Congress. San Diego, CA, November.

2004 “Special Considerations in Bipolar Disorder.” World Psychiatric Association International Congress, Treatments in Psychiatry: an update. Florence, Italy, November.

2004 “Mood Disorders.” *Chair*, New Research Session at the World Psychiatric Association International Congress, Treatments in Psychiatry: an update. Florence, Italy, November.

2004 “Special Considerations in Bipolar Disorder.” Bipolar Global Medical Conference. Rome, Italy, September.

2004 "Efficacy and Safety of Anticonvulsants and Antipsychotics in the Management of Bipolar Disorder.**”** *Faculty*,Bipolar Educational Consortium Regional Meeting. Grapevine, Texas, June.

2004 **“**Reproductive Endocrine Function in Women Treated for Bipolar Disorder.” Annual Meeting, American Psychiatric Association. New York, NY, May.

2004 “Estrogen, Mood, and Cognition: Circa 2003.” Symposium at the Annual Meeting, American Psychiatric Association. New York, NY, May.

2004 “New Perspectives on the Diagnosis and Management of Depression and Anxiety Disorders in Primary Care ” (*Chair)*, North American Women's Healthcare Forum. Anaheim, CA, March.

2004 “Metabolic Issues in Psychiatry.” *Chair*, Psychopharmacological Update in Bipolar Disorder. Palo Alto, CA, October.

2004 “Reproductive Health of Women Treated for Bipolar Disorder.” *Chair*, Psychopharmacological Update in Bipolar Disorder. Palo Alto, CA, October.

2004 “Mood & Anxiety Disorders.” First Annual Continuing Medical Education Conference. Los Angeles, CA, April.

2004 “Update on Bipolar Disorders.” Grand Rounds, Kaiser Permanente. Union City, CA, April.

2004 “Women’s Issues with Bipolar Disorder.” Grand Rounds, University of Texas. San Antonio, TX, March.

2004 “Estrogen, Mood, and Cognition in Postmenopausal Women.” Grand Rounds,

University of Vermont. Burlington, VT, February.

2004 “ERT, Mood and Cognition in Postmenopausal Women.” Grand Rounds, Department of Obstetrics and Gynecology, Stanford School of Medicine. Stanford, CA, January.

2004 “Insulin Resistance May Link Affective Disorders and Alzheimer’s Disease.” Santa Clara Association of Psychiatrists. Santa Clara, CA, January.

2003 “Estrogen, Mood Disorders and Cognition Across the Lifespan.” *Co*-*Chair*, Annual Meeting, American Psychiatric Association. San Francisco, CA, May.

2003 “Bipolar Disorder Across the Life Cycle: Reproductive Health and Metabolic Correlates in Women Receiving Treatment for Bipolar Disorder.” Symposium at the Annual Meeting, American Psychiatric Association. San Francisco, CA, May.

2003 “Anxiety and Pregnancy: A Normal Reaction to Stress, or More?” *Chair*, Annual Clinical Meeting, American College of Obstetricians and Gynecologists. New Orleans, LA: April.

2003 “New Perspectives on the Diagnosis and Management of Anxiety Disorders in Primary Care.” *Chair*, North American Women's Healthcare Forum. Anaheim, CA: March.

2003 “Women’s Issues with Bipolar Disorder.” Grand Rounds, East Bay and San Mateo County Psychiatry. San Mateo, CA: November.

2003 “ERT, Mood and Cognition in Postmenopausal Women.” Grand Rounds, Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine. Stanford, CA: October.

2003 “Female-specific Presentation of Bipolar Disorder.” Grand Rounds, Department of Psychiatry, UC San Francisco. San Francisco, CA: October.

2003 “Estrogen, Mood Disorders and Cognition Across the Lifespan.” Nevada Association of Psychiatrists. Las Vegas, NV: August.

2002 “Estrogens Versus Antidepressant Treatment of Perimenopausal Depression.” New Strategies for Treating Depression in Women Symposium, CME Lecture, American College of Obstetricians and Gynecologists. Los Angeles, CA: May.

2002 “Reproductive Issues in the Female Patient with Bipolar Disorder.” Ground Rounds, San Francisco General Hospital. San Francisco, CA: November.

2002 “Estrogen Replacement Therapy and Mood in Postmenopausal Women.” Northern California Association of Obstetricians and Gynecologists. Sacramento, CA: November.

2002 “Remarkable Revelations and Recommendations from Rhetoricians with Redoubtable Reputations.” Fall 2002 Psychiatric Update, CME Conference. Madison, WI: November.

2002 “Diagnosis and Treatment of Depression.” UCLA Conference for Primary Care Physicians. Las Vegas, NV: April.

2002 “Depression and Women.” UCLA Conference for Primary Care Physicians. Las Vegas, NV: April.

2002 “Anticonvulsant Drug Use: Reproductive and Metabolic Health Considerations.” *Keynote Speaker*, CME Lecture Series. Chicago, IL; Houston, TX; Dallas, TX; Dearborn, MI; Minneapolis, MN; San Diego, CA: January-April.

2002 “Estrogen Replacement Therapy in the Treatment of Depression in Peri- and Postmenopausal Women.” Grand Rounds, Cedars Sinai Medical Center. Los Angeles, CA: January.

2001 **“**Depression in Women with Premenstrual Dysphoric Disorder.” Targeting Undiagnosed Depression in Woman of Childbearing Age: Biological and Psychological Perspectives Symposium, CME Lecture, American College of Obstetricians and Gynecologists. Chicago, IL: April.

2001 “Depression and Comorbid Conditions: A Psychiatric Perspective.” CME Lecture, Psychiatric Disorders Across a Woman’s Life Span. Coronado, CA: December.

2001 “Update on the treatment of Major Depression.” CME Lecture, Valley

Presbyterian Hospital. Van Nuys, CA: May.

2001 “Hormones From Hell.” Grand Rounds, St. Joseph’s Hospital. Orange, CA: May.

2001 “Medication Status and Reproductive Endocrine Function in Women with Bipolar Disorder.” Grand Rounds, Department of Pediatric Neurology, UCLA Medical Center. Los Angeles, CA: April.

2001 “Psychopharmacology of Female Specific Mood Disorders.” Grand Rounds, Department of Internal Medicine, Cedar Sinai Medical Center. Los Angeles, CA: April.

2000 “The Role of Estrogen Replacement Therapy on Mood and Cognition in Postmenopause.” *Chair*, National Conference, American Psychiatric Association. Chicago, IL: May.

2000 “Update on the Treatment of Menopause-Related Depression.” CME Lecture, St. John’s Hospital. Santa Monica, CA: November.

2000 “Women’s Issues with Bipolar Disorder.” Grand Rounds, San Francisco General Hospital. San Francisco, CA: October.

2000 “Female-Specific Mood Disorders.” Grand Rounds, Consultation-Emergency Service, UCLA Neuropsychiatric Institute and Hospital. Los Angeles, CA: October.

2000 “Estrogen and Cognition.” CME Lecture, Iris Cantor Women’s Health Center, UCLA Medical Center. Los Angeles, CA: October.

2000 “Reproductive Issues in the Female Patient with Bipolar Disorder.” Grand Rounds, University of New Mexico School of Medicine. Albuquerque, NM: September.

2000 “Treating the Female Patient: PMDD and Depression.” CME Lecture. San Diego, CA: September.

2000 “Gender Differences in the Treatment of Mood Disorders.” CME Lecture. San Francisco, CA: September.

2000 “Prevention of Alzheimer’s Disease in Women: Where Are We at the Millennium?” CME Lecture, 4th Annual Controversies in Women’s Heath. Anaheim, CA: August.

2000 “Mood Disorders in Women.” Grand Rounds, University of Southern California. Los Angeles, CA: August.

2000 “Prevalence of Polycystic Ovarian Syndrome in Women with Bipolar Illness Receiving Mood Stabilizers.” PCOS: A Brand New Day, PCO Support International Conference 2000 of the Polycystic Ovarian Syndrome Association. San Diego, CA: June.

1999 “Gender Issues in the Diagnosis and Treatment of Bipolar Disorder.” Grand Rounds, Carondolet Hospital. Tucson, AZ: December.

1999 “Gender Issues in the Diagnosis and Treatment of Bipolar Disorder.” Grand Rounds, St. Elizabeth’s Hospital. Washington, D.C.: October.

1999 “Gender Issues in the Diagnosis and Treatment of Bipolar Disorder.”

Grand Rounds, Walter Reed Medical Center. Washington, D.C.: October.

1999 “Estrogen and the Brain.” CME Lecture. Anaheim, CA: July.

1999 “Neurosteroid Responses to Serotonergic Challenge in Women with PMS and Controls.” Department of Experimental Biology, Division of Pharmacology, University of Cagliari. Cagliari, Italy: June.

1999 “Update on Women’s Mental Health Issues.” Long Beach, CA: May.

1999 “Update on Gender Issues in the Diagnosis and Treatment of Bipolar Disorder.” CME Lecture, Kaiser Permanente. Panorama City, CA: April.

1998 “Female-Specific Mood Disorders.” Grand Rounds, Consultation-Emergency Service, UCLA Neuropsychiatric Institute and Hospital. Los Angeles, CA.

1998 “Mental Well-Being.” Total Health for Women, UCLA Medical Center. Los Angeles, CA: October.

1998 “Estrogen and Alzheimer’s Disease.” CME Lecture, UCLA Conference,Controversies in Women’s Health. Los Angeles, CA: May.

1998 “New Approaches to Premenstrual Dysphoric Disorder.” CME Lecture, Kaiser Permanente. Bellflower, CA: March.

1997 “Neurobiology of Reproductive Hormones: Implications with Regard to Mood and Behavior in Women.” Women’s Mental Health: A Treatment Update II, Southern California Psychiatric Society. Beverly Hills, CA.

1997 “Women’s Mental Health Issues Throughout the Lifecycle.” SCPS Conference. Los Angeles, CA.

1997 “Mental Well-Being.” Total Health for Women Conference, UCLA Medical Center. Los Angeles, CA.

1997 “Violence Against Women.” Kaiser Permanente Women’s Mental Health Symposium. South Lake Tahoe, CA.

1997 “Premenstrual Dysphoric Disorder, Pathophysiology and Treatment: An Update.” Kaiser Permanente Women’s Mental Health Symposium. South Lake Tahoe, CA.

1997 “Mood Disorders Across the Woman’s Life Cycle.” Panelist, Issues in Women’s Health, Annual Meeting of Commercial Real Estate Women. Los Angeles, CA.

1997 “Mental Illness in Women.” National Alliance of Mentally Ill. Anaheim, CA.

1997 “Sex Steroids and Mood.” Grand Rounds, Department of Obstetrics and Gynecology, UCLA Medical Center. Los Angeles, CA.

1997 “Role of Serotonin in Pathophysiology of Premenstrual Dysphoric Disorder.” Grand Rounds, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center. Los Angeles, CA.

1996 “Premenstrual Dysphoric Disorder.” Grand Rounds, Department of Psychiatry, Cedars-Sinai Medical Center. Los Angeles, CA.

1986-89 “Chronic pelvic pain.” Central Institute for Postgraduate Medical Education. Moscow, U.S.S.R.

**POSTER PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS:**

1. **Rasgon, NL**, Wroolie, T., Watson-Lin, K., Kramer, A., & Balzafiore, D. Open label trial of magnesium l-threonate for adults with mild to moderate Alzheimer’s disease. Poster accepted at the meeting of the Society for Neuroscience, San Diego, CA, November 12-16, 2016.
2. Kramer, A, Balzafiore, DR, Watson, KL, Wroolie, T, & **Rasgon, NL**. Magnesium l-threonate for the enhancement of learning and memory in dementia. Poster presented at the meeting of the California Psychological Association, Irvine, California, April 2016
3. Williams, KE, Balzafiore, DR, Wroolie, T, Watson, KL, Anaya, I, Robakis, T, & **Rasgon, NL**. “Treatment Resistance” in postpartum depression: An exploratory study. Poster presented at the meeting of Perinatal Mental Health, Northwestern University, Chicago, Illinois, November 2015
4. Watson, KT, Wroolie, T, Robakis, T, Balzafiore, DR & **Rasgon, NL**. Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response. Poster presented at the meeting of the Society for Neuroscience, Hollywood, FL, October 17-21, 2015
5. Balzafiore, DR., Kim, H, Goffin, KC, **Rasgon, N.**, & Ketter, TA. Prevalence and clinical characteristics of lifetime eating disorder comorbidity in bipolar disorder patients. Poster presented at the meeting of the International Society for Bipolar Disorders, Toronto, Ontario, Canada, June 3-6, 2015
6. Robakis, TK, Holtzman, J, Stemmle, PG, Reynolds-May, MF, Kenna, HA, & **Rasgon, NL**. Lamotrigine and GABAA­ Receptor Modulators Interact with Menstrual Cycle Phase and Oral Contraceptives to Regulate Mood in Women with Bipolar Disorder. Poster presented at the Annual Meeting of Organization for the Study of Sex Differences, Stanford University, Palo Alto, California, April 21-23, 2015
7. Wroolie, T., Kenna, H., & **Rasgon, N.**, Association Between Direct and Indirect Measures of Insulin Resistance and Cognition in Euthymic Adults with Histories of Major Depressive Disorder. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology, Phoenix, Arizona, December 2014
8. Kenna, H, Sheau, K, Wroolie, T, Kelley, RG, Williams, K, Reiss, A, & **Rasgon, N.** Differential Effects of Estrogen Hormone Therapy on CA1 Hippocampal Subfield Volume Change Over a 2-Year Observation Period in Postmenopausal Women at Risk for Alzheimer’s Disease: Conjugated Equine Estrogen Versus Estradiol. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL, December 2013
9. Williams KE, Wroolie TE, Hoyman L, Peters L, **Rasgon NL**. Clinical and Demographic Characteristics of Women Treated for Postpartum Depression in a University Perinatal Clinic,

Perinatal Mental Health: Optimizing Maternal Treatment to Improve Infant Outcomes Conference, Chicago, Illinois, November 6-8, 2013.

1. Geist C, Silverman D, Kenna H, **Rasgon N**. Lower Temporal and Frontal Metabolism in Postmenopausal Women Taking Progesterone-Plus-Estrogen Compared to Women Taking Unopposed Estrogen. Poster presented at the World Molecular Imagining Conference, Montreal, Canada: September, 2009.
2. Marsh WK, Ketter TA, **Rasgon NL**. Mood States in Menopausal Transition Age Women with Bipolar Disorder: Age and Gender Comparison. Poster presented at the Annual Meeting, American Psychiatric Association, San Francisco, CA; May 16-21, 2009.
3. Geist CL, Silverman DH, Kenna H, **Rasgon NL**. Verbal memory performance of postmenopausal women on estradiol therapy is positively correlated with regional brain metabolism in receptive language and auditory association areas. Annual Meeting of the Society of Nuclear Medicine, Toronto, CA, June 13-17, 2009.
4. Vemuri M, Ketter TA, Kenna H, Saha U, Morenkova A, Wang P, **Rasgon NL**. Gender Comparison of Lipids in Patients with Bipolar Disorder. Poster presented at the Annual Meeting, American Psychiatric Association, San Francisco, CA; May 16-21, 2009.
5. Awaad R, Kenna H., **Rasgon N.**  Perceptions of Mental Health Disorders in American Muslim Women. Poster presented at the Annual Meeting, American Psychiatric Association, San Francisco, CA; May 16-21, 2009.
6. **Rasgon N**, Kenna H, Geist C, Powers B, Wroolie T, Williams K, Silverman D. Regional cerebral metabolism and neuropsychological performance among healthy postmenopausal users of estrogen therapy. Poster session presented at the annual meeting of the Society for Biological Psychiatry, Washington, D.C. May, 2009.
7. Bauer M, Glenn T, Grof P, L **Rasgon NL**, Marsh W, Sagduyu K, Alda M, Murray G, Quiroz D, Malliaris Y, Sasse J, Whybrow PC.  Latitude, climate, season and self-reported mood in bipolar disorder. APA 2009 San Francisco.
8. Geist CL, Silverman DH, Kenna H, **Rasgon NL**. Lower temporal and frontal metabolism in postmenopausal women taking progesterone-plus-estrogen compared to women taking unopposed estrogen. (2009) UCLA
9. Geist CL, Silverman DH, Kenna H, **Rasgon NL**. Verbal memory performance of postmenopausal women on estradiol therapy is positively correlated with regional brain metabolism in receptive language and auditory association areas. (2009) UCLA
10. **Rasgon NL**, Kenna HA, Stemmle P, Vemuri M, Ketter T. (2009, December). Neurotrophins, inflammatory markers, and metabolic function in women with ipolar Disorder.  Presented at the 47th Annual American College of Neuropsychopharmacology.
11. Glenn G, Bauer M, Grof P, **Rasgon NL**, Marsh W, Sagduyu K, Alda M, Lewitzka U, Sasse J, Kozuch-Krolik E, Whybrow PC.  Employment status and subsyndromal symptoms in bipolar disorder.  Pittsburgh International Conference on Bipolar Disorder 2009.
12. **Rasgon, NL**. Lamotrigine in the Treatment of Bipolar Disorder in Reproductive-Aged Women. Biological Psychiatry Congress, Paris, France, 2009.
13. **Rasgon N**, Kenna H, Powers B, Keller K, Wang P, Ketter T. Effects of Ziprasidone on Insulin Sensitivity and Glucose Utilization in Overweight and Obese Patients with Bipolar Disorder. Poster presented at the 47th Annual Meeting of the American College of Neuropsychopharmacology, Scottsdale, AZ; December, 2008.
14. **Rasgon NL**, Kenna HA, Stemmle PG, Reynolds MF, Vemuri M, Wang P, Ketter T. “Metabolic Function in Women with Bipolar Disorder and Controls.” Poster presented at the 46th Annual Meeting of the American College of Neuropsychopharmacology, Scottsdale, AZ; December, 2008.
15. **Rasgon NL**, Kenna HA, Stemmle PG, Reynolds MF, Vemuri M, Wang P, Ketter T. Reproductive abnormalities in women with Bipolar Disorder. Poster presented at the 6th Annual Meeting of the Androgen Excess and PCOS Society, San Francisco, CA. November, 2008.
16. Silverman D, Geist C, Kenna H, **Rasgon N**. “Effects of stopping postmenopausal hormone therapy on regional brain metabolism in a prospective randomized discontinuance /continuance trial”. Annual meeting, World Molecular Imaging Congress. Nice, France. September, 2008.
17. Holcomb, M.G, Gomez, R.G., Wroolie, T.E., Williams, K.E., Kenna, H., Powers B.N., & **Rasgon, N**. “Age and sleep disturbance effects on cognition in at-risk women.” Annual Meeting, American Psychological Association: Division 40. August 2008, Boston, MA.
18. **Rasgon N**, Kenna H, Geist C, Powers B, Wroolie T, Williams K, Silverman D. “Regional cerebral metabolism and neuropsychological performance among healthy postmenopausal users of estrogen therapy”. Annual meeting, Society for Biological Psychiatry, Washington, D.C. May, 2008.
19. Geist C, **Rasgon N**, Kenna H, Powers B, Wroolie T, Silverman D. “Decline of inferior parietal brain metabolism in postmenopausal women who discontinue hormone therapy”. Annual meeting, Society of Nuclear Medicine. New Orleans, Louisiana. May, 2008.
20. Vemuri M, **Rasgon N**, Arce H, Nguyen N, Saha U, Wang P, Ketter, T, “High Rates of

Dyslipidemia in outpatients with Bipolar Disorder”.  Annual Meeting, American

Psychiatric Association. Washington, D.C.: May 3-8, 2008.

1. Glenn T, Grof P, **Rasgon NL**, Marsh W, Sagduyu K, Alda M, Quiroz D, Whybrow PC, Bauer M. “Employment Status and Subsyndromal Symptoms in Bipolar Disorder”. Annual Meeting, American Psychiatric Association. Washington, D.C.: May 3-8, 2008.
2. Bauer M., Glenn T, Grof P, **Rasgon NL**, Alda M, Whybrow PC. “Changes in Sleep Duration and Changes in Mood in Bipolar Disorder”. Annual Meeting, American Psychiatric Association. Washington, D.C.: May 3-8, 2008.
3. **Rasgon, N**., Kenna, H.A., Williams, K.E. & Schatzberg, A.F. (2007, December). “Adjunctive rosiglitazone treatment in MDD patients with insulin resistance”. Poster session presented at the American College of Neuropsychopharmacology 46th Annual Meeting. Boca Raton, Florida: December 9-13, 2007.
4. Brannan, S, Lane R, Eagle G, Peskind E, Soininen H, **Rasgon N**, Darreh-Shori T. “The Effects of ChoIs on CSF Cholinesterase Activity in AD Patients.” Poster presentation at the American College of Neuropsychopharmacology 46th Annual Meeting. Boca Raton, Florida: December 9-13, 2007.
5. **Rasgon NL**, Stemmle PG, Kenna HA, Wang PW, Hill SJ, Ketter, TK. “Insulin Resistance and Hyperlipidemia in Women with Bipolar Disorder.” Poster presentation at the American College of Neuropsychopharmacology 46th Annual Meeting. Boca Raton, Florida: December 9-13, 2007.
6. Zappert, LN, Wroolie TE, Keller J, Williams JE, Shelton, S.D. **Rasgon, NL**. “Psychosocial correlates of escitalopram treatment response in women with mid-life depression.” Paper submitted for presentation at the British Association for Psychopharmacology, 2007 Summer Meeting, Harrogate, England, United Kingdom, July 22-25th, 2007.
7. Bauer M, Grof P,Glenn T, **Rasgon NL**, Sasse J, Whybrow PC. “Self-Reported Depression and Minimum Length of Depression Episodes in Bipolar Disorder”. Seventh International Conference on Bipolar Disorder. Pittsburgh, Pennsylvania. June 7-9, 2007.
8. Glenn T, Whybrow PC, **Rasgon NL**, Grof P, Alda M, Baethge C, Bauer M. “Approximate Entropy of Self-Reported Mood Prior to Episodes in Patients With Bipolar Disorder”. Seventh International Conference on Bipolar Disorder. Pittsburgh, Pennsylvania. June 7-9, 2007.
9. Tan V, **Rasgon N**. “Adrenal Insufficiency Disguised and Quetiapine a Culprit.” Annual Meeting, American Psychiatric Association. San Diego, CA: May 19-24, 2007.
10. Tan V, **Rasgon N**. “Adrenal Insufficiency Disguised and Quetiapine a Culprit.” Poster Presentation at the Institute on Psychiatric Services in New Orleans, LA. 2007.
11. **Rasgon N**. “Functional brain imaging studies in estrogen depleted postmenopausal women with major depressive disorder.” Society of Biological Psychiatry's 62nd Annual Scientific Program and Convention, San Diego, California, May 17-19, 2007.
12. Dunkin, J, **Rasgon N**, Zeller M, Wager-Steh K, David S, Altshuler L, Rapkin A. “Relationships Between Neurophsychological Deficits and Social Functioning in Depressed and Nondepressed Postmenopausal Women.” Annual Meeting of the International Neuropsycholgical Society, Portland, Oregon: February 7-10, 2007.
13. **Rasgon NL**, Geist CL, Kenna H, Wroolie TE, Powers B, Shelton S, Phelps ME, Silverman DHS. “Changes in Regional Brain Metabolism and Insulin Resistance in Postmenopausal Women”. 53rd Annual Meeting, Society of Nuclear Medicine, San Diego, California: June 3-7, 2006.
14. Marsh WK, Terrence KA, Culver J, Nam J, Holland A, **Rasgon NL**. “Gender Differences in Quetiapine Use and Response in Patients with Bipolar Disorder”. Annual Meeting, American Psychological Association. Toronto, Canada: May 20-25, 2006.
15. **Rasgon NL,** Marsh W, Grof P, Sagduyu K, Munoz RA, Glenn T, Reynolds MF, Whybrow PC, Bauer M. “Antipsychotics and Anticonvulsants: The Risk of Menstrual Abnormalities in Women with Bipolar Disorder”. Annual Meeting, American Psychological Association. Toronto, Canada: May 20-25, 2006.
16. Kenna H, **Rasgon N**, Wong M, Bauer M. “Hypothalamic-Pituitary-End Organ Interactions in Women with Bipolar Depression.” Annual Meeting, Society of Biological Psychiatry. Toronto, Canada: May 17-19, 2006.
17. Bauer M, London ED, Berman SM, **Rasgon N**, Mandelkern MA, Voytek B, Whybrow PC. “Regional Cerebral Metabolism and Anxiety Symtoms in Bipolar Depression: Effects of Levothyroxine.” American College of Neuropsychopharmacology. Waikoloa, Hawaii: December 11-15, 2005. (Neuropsychopharmacology 30, Suppl 1: 96-97)
18. **Rasgon NL**, Reynolds MF, Zappert LN, Kenna HA. “Depression-insulin Resistance Link.” American College of Neuropsychopharmacology. Waikoloa, Hawaii: December 11-15, 2005.
19. **Rasgon NL**, Zappert LN, Wroolie TE, Williams KE, Keller J, Shelton SD, Reynolds MF, Gumina HK. “Neuropsychological Effects of Escitalopram Treatment in Middle-aged Women.” 2nd International Congress on Brain & Behavior. Thessaloniki, Greece: November 17 -20, 2005.
20. Wroolie TE, Keller J, Williams KE, Shelton SD, Zappert LN, **Rasgon NL**. “Neuropsychological Effects of Escitalopram Treatment in Middle-aged Women.” National Association of Neuropsychology Conference. Tampa, Florida: October 19-22, 2005.
21. Wroolie TE, Keller J, Williams KE, Shelton SD, Zappert LN, **Rasgon NL**. “Neuropsychological Effects of Escitalopram Treatment in Middle-aged Women.” American Psychological Association Convention. Washington, D.C.: August 18-21, 2005.
22. Geist CL, **Rasgon NL**, Phelps ME, Silverman DHS. “Loss of the Normal Correlation Between Thalamic and Striatal Metabolic Activities in Postmenopausal Women Not on Estrogen Replacement Therapy.” Annual Meeting, Society of Nuclear Medicine. Toronto, Canada: June 16-22, 2005.
23. Marsh WK, Zappert LN, Williams EK, Templeton AJ, Reynolds MF, Ketter TA, **Rasgon NL**. “Clinical Course of Bipolar Disorder During Pregnancy in Women Receiving Minimal or No Prescription Psychotropic Medication.” Sixth International Conference on Bipolar Disorder. Pittsburgh, PA: June 16-18, 2005.
24. Reynolds M, **Rasgon N**, Elman S, Saad M, Frye M, Bauer M, Altshuler L, Marsh W. “Prospective Longitudinal Endocrine Study of Women Treated for Bipolar Disorder.” Sixth International Conference on Bipolar Disorder. Pittsburgh, PA: June 16-18, 2005.
25. Zappert L, Glenn T, Bauer M, Elman S, Frye M, Altshuler L, Gitlin M, Marsh W, Reynolds M, Kenna H, Templeton A, Shelton S, **Rasgon N**. “Effects of Gender on Mood in the Clinical Course of Bipolar Disorder.” Sixth International Conference on Bipolar Disorder. Pittsburgh, PA: June 16-18, 2005.
26. Rapkin A, Concas A, Biggio G, Morgan M, **Rasgon R**. “Neuroactive Steroids in PMS and Menopausal Major Depressive Disorder: Effects of SSRI’s and Treatment Response.” Annual Meeting, Society of Biological Psychiatry. Vienna, Austria: June, 2005.
27. Bauer M, Grof P, **Rasgon N**, Bschor T, Glenn T, Whybrow PC. “Temporal Relation Between Sleep and Mood in Bipolar Disorder.” Annual Meeting, American Psychiatric Association. Atlanta, GA: May 21-26, 2005.
28. Bauer M, Neuhaus K, Sasse J, Schlosser T, Bschor T, **Rasgon N**, Grof P, Gyulai L, Glenn T, Whybrow PC. “Validation of ChronoRecord Self-Reporting Software by Inpatients with Mania.” Annual Meeting, American Psychiatric Association. Atlanta, GA: May 21-26, 2005.
29. Marsh W, Templeton A, Ketter T, **Rasgon N**. “Clinical Course of Bipolar Disorder Through Perimenopause: Chart Review.” Annual Meeting, American Psychiatric Association. Atlanta, GA: May 21-26, 2005.
30. **Rasgon N**. Presentation, title TBA. “Children of Alzheimer Parent – What Are the Risks?” Workshop. San Diego, CA: March 6-7, 2005
31. Jarvik L, Harrison T, Holt L, Larson S, Steh B, Yaralian P, Jimenez E, LaRue A, Matsuyama S, **Rasgon N**, Schaeffer J. “Alzheimer Offspring 20 Years Later - No Significant Cognitive Decline?” Fifty Seventh Annual Scientific Meeting, The Gerontological Society of America. Washington, D.C.: November 19-23, 2004.
32. Geist CL, **Rasgon NL**, Bauer MJ, Whybrow PC, Phelps ME, Silverman DHS. “Mood and Hormones: Regional Cerebral Metabolism in Hypothyroid and Hypoestrogen Depression.” Thirty Fourth Annual Meeting of the Society for Neuroscience. San Diego, CA: October 23-27, 2004.
33. Dunkin J, **Rasgon NL**, Wagner-Steh K, David S, Altshuler L, Rapkin A. “Predictors of Cognitive Performance in Healthy Postmenopausal Women.” Fifth International Congress of Neuropsychiatry. Athens, Greece: October 14-18, 2004.
34. Dunkin J, **Rasgon NL**, Wagner-Steh K, David S, Altshuler L, Rapkin A. “Use of Regression-Based Change Scores to Measure Effects of Estrogen Replacement Cognition in Healthy, Postmenopausal Women.” Fifth International Congress of Neuropsychiatry. Athens, Greece: October 14-18, 2004.
35. Zappert L, Glenn T, Bauer M, Elman S, Frye M, Altshuler L, Gitlin M, **Rasgon NL**. “Gender and Mood in the Clinical Course of Bipolar Disorder”. Poster presentation at the Bipolar Global Medical Conference. Rome, Italy: September 20-22, 2004.
36. Harrison T, Larson S, Yaralian P, Holt L, Steh B, LaRue A, Matsuyama S, **Rasgon N**, Schaeffer J, Jarvik L. “A Longitudinal Study of the Adult Children of Alzheimer Patients.” American Association for Geriatric Psychiatry. Baltimore, MD: 2004.
37. Trendelenburg M, Sasse J, Schlosser T, Whybrow P, Grof P, Gyulai L, **Rasgon N**, Glenn T, Bschor T, Bauer M. “Using Software to Improve Longitudinal Studies: Self-Reporting with ChronoRecord in Bipolar Disorder.” Acta Psychiatrica Scandinavica 2003; 423(110):39-40. Fourth European Stanley Conference on Bipolar Disorders. Aarhus, Denmark: September 23-25, 2004.
38. Harrison T, Holt L, Jimenez E, Larson S, LaRue A, Matsuyama S, **Rasgon N**, Schaeffer J, Steh B, Yaralian P, Jarvik L. “UCLA/VA 20-Year Prospective Study of Adult Children of Alzheimer Patients.” Ninth Annual Research Conference on Aging, UCLA Center on Aging. Los Angeles, CA: June 27, 2004.
39. Geist CL, **Rasgon NL**, Bauer MJ, Whybrow PC, Phelps ME, Silverman DH. “Regional Brain Metabolism in Depressed Women: Comparison of Hypothyroidism and Hypoestrogenism.” 2004 Meeting, Society of Nuclear Medicine. Philadelphia, PA: June 2004.
40. Bauer M, **Rasgon N**, Grof P, Bschor T, Gyulai L, Glenn T, Whybrow P. “Sleep and Mood in Patients Treated for Bipolar Disorder: A Time Series Approach.” Poster presentation at New Clinical Drug Evaluation Unit. Phoenix, AZ: June 1-4, 2004.
41. **Rasgon N**, Bauer M, Grof P, Bschor T, Gyulai L, Glenn T, Whybrow P. “Mood and Menstrual Cycle in Bipolar Disorder: A Time Series Approach.” Annual Meeting, American Psychiatric Association. New York, NY: May 1-6, 2004.
42. Bauer M, **Rasgon N**, Grof P, Bschor T, Gyulai L, Glenn T, Whybrow P. “Mood and Sleep in Patients Treated for Bipolar Disorder: A Time Series Approach.” Annual Meeting, American Psychiatric Association. New York, NY: May 1-6, 2004.
43. Harrison T, Steh B, Matsuyama S, Yarlian P, Larson S, Holt L, Schaeffer J, LaRue A, **Rasgon N**, Jarvik L. “A 20-Year Prospective Study of Adult Children of Alzheimer Patients.” Annual Meeting, American Psychiatric Association. New York, NY: May 1-6, 2004.
44. Harrison T, Larson S, Yaralian P, Holt L, Steh B, LaRue A, Matsuyama S, **Rasgon N**, Schaeffer J, Jarvik L. “A 20-Year Follow-Up of First Degree Relatives of Alzheimer Patients.” Joint Conference of the American Society on Aging and The National Council on the Aging. San Francisco, CA: 2004.
45. Parsons TD, Miller KJ, **Rasgon N**, Van Herle K, Whybrow PC, Bauer M. “Improved Verbal Memory Associated with Hypothyroid Treatment.” Annual Meeting, International Neuropsychological Society. Baltimore, MD: February 2004. (Journal of International Neuropsychological Society 2004 Feb:181-182.)
46. Dunkin J, **Rasgon N**, Wagner-Steh K, David S, Altshuler L, Rapkin A. “Predictors of cognition functioning in healthy, postmenopausal women.” Annual Meeting, International Neuropsychological Society. Baltimore, MD: February 2004.
47. Bauer M, London ED, **Rasgon N**, Berman S, Frye M, Altshuler L, Mandelkern M, Woods R, Mazziotta J, Whybrow P. “Supraphysiological Doses of Levothyroxine Alter Regional Cerebral Metabolism in Bipolar Depression.” Forty Second Annual Meeting, American Collage of Neuropsychopharmacology. San Juan, Puerto Rico: December 7-11, 2003.
48. Harrison T, Freimer N, Holt L, Larson S, Matsuyama S, **Rasgon N**, Schaeffer J, Yaralian P, Jarvik L, Steh B, LaRue A. “Children of Alzheimer Patients: A 20-Year Prospective Study.” Annual Meeting, Gerontological Society of America. San Diego, CA: November 21-25, 2003.
49. **Rasgon NL**, Magnuson C, Johansson A, Pedersen N, Gatz M. ”Estrogen Use and Risk for Cognitive Impairment in Female Swedish Twins: Preliminary Analyses.” The 4th Neurobiology of Aging Conference. New Orleans, LA: November 6-7, 2003.
50. Miller KJ, Parsons TD, **Rasgon N**, Van Herle K, Whybrow PC, Bauer M. “Hypothyroidism and Specific Memory Deficits.” National Academy of Neuropsychology. Dallas, TX: October 2003. (Res Clin Neuropsych 2003; 18(7):729-730.)
51. Harrison T, Freimer N, Holt L, Larson S, Matsuyama S, **Rasgon N**, Schaeffer J, Yaralian P, Jarvik L. “UCLA/VA Follow-up Study of Alzheimer Families.” Eleventh International Congress, International Psychogeriatric Association. Chicago, IL: August 17-22, 2003.
52. Miller KJ, Parsons TD, **Rasgon N**, Van Herle K, Whybrow PC, Bauer M. “Verbal Memory Deficits Associated with Untreated Hypothyroidism.” Paper presented at 2nd Annual UCLA Learning and Memory Conference, NPI. Los Angeles, CA: June 2003.
53. Bauer M, Grof P, **Rasgon N**, Gyulai L, Glenn T, Whybrow PC.  “Number of Medications and Self-reported Mood in Patients with Bipolar Disorder.”  Fifth International Conference on Bipolar Disorder. Pittsburgh, PA: June 12-14, 2003.
54. Bauer M, **Rasgon N**, Grof P, Gyulai L, Glenn T, Whybrow PC.  “Mood Patterns in Patients with Bipolar Disorder: Influence of Antidepressants.”  Fifth International Conference on Bipolar Disorder. Pittsburgh, PA: June 12-14, 2003.
55. **Rasgon N**, Bauer M, Grof P, Gyulai L, Glenn T, Whybrow PC. “Gender Differences in the Mood Patterns of Patients with Bipolar Disorder.”  Fifth International Conference on Bipolar Disorder. Pittsburgh, PA: June 12-14, 2003.
56. Miller KJ, Parsons TD, **Rasgon N**, Van Herle K, Whybrow PC, Bauer M. “Neuropsychological Efficacy of Hypothyroid Treatment.” Proceedings and Abstracts, 8th Annual UCLA Research Conference on Aging. Los Angeles, CA: June 2003.
57. Dunkin J, **Rasgon N**, Wagner-Steh K, David S, Elman S, Altshuler L, Rapkin A. “A Placebo-Controlled Study of the Effects of Estrogen Replacement Therapy on Cognition in Postmenopausal Women.” Proceedings and Abstracts, 8th Annual UCLA Research Conference on Aging. Los Angeles, CA: June 2003.
58. **Rasgon NL**, Altshuler LL, Birtan JA, Elman S, Frye MA. “Menstrual Abnormalities in Women with Bipolar Disorder.” Annual Meeting, American Psychiatric Association. San Francisco, CA: May 17-22, 2003.
59. **Rasgon N**, Bauer M, Grof P, Gyulai L, Glenn T, Whybrow PC. “Influence of Gender on Clinical Course in Bipolar Disorder.” Annual Meeting, American Psychiatric Association. San Francisco, CA: May 17-22, 2003.
60. Bauer M, Grof P, **Rasgon N**, Gyulai L, Glenn T, Whybrow PC. “Relation Netween Number of Medications and Self-reported Mood in Bipolar Disorder.” Annual Meeting, American Psychiatric Association. San Francisco, CA: May 17-22, 2003.
61. Bauer M, **Rasgon N**, Grof P, Gyulai L, Glenn T, Whybrow PC. “Mood Changes Related to Antidepressants in Patients with Bipolar Disorder.” Annual Meeting, American Psychiatric Association. San Francisco, CA: May 17-22, 2003.
62. **Rasgon NL**. “Estrogen Use and Brain Metabolic Change in Postmenopausal Women at Risk for Alzheimer’s Disease.” Annual Meeting, Society of Biological Psychiatry. San Francisco, CA: May 15-17, 2003.
63. Dunkin JJ, **Rasgon NL**, David S, Elman S, Altshuler L, Rapkin A. “Effects of Estrogen Replacement Therapy on Cognition in Postmenopausal Women: A Placebo-Controlled Trial.” Annual Meeting, International Neuropsychological Society. Honolulu, HI: February 2003. (Journal of International Neuropsychological Society 2003;9:301.)
64. Silverman DHS, Geist CL, Marseille DM, Van Herle K, **Rasgon NL**, Martinez D, Miller KJ, Haselrig T, Van Herle A, Whybrow PC, Czernin J, Phelps ME, Bauer MJ. “Neural Substrates for Cognitive Impairment in Patients with Hypothyroidism.” Annual Meeting, Society for Neuroscience. Orlando, FL: 2002.
65. **Rasgon NL**, Jarvik G, Jarvik L. “Affective Disorders and Alzheimer’s Disease: A Missing Link Hypothesis.” 8th International Conference on Alzheimer’s Disease and Related Disorders. Stockholm, Sweden: July 20-25, 2002.
66. **Rasgon NL**, Magnuson C, Johansson ALV, Pedersen N, Gatz M. “Estrogen Use and Risk for Cognitive Impairment in Female Swedish Twins: Preliminary Analyses.” 8th International Conference on Alzheimer’s Disease and Related Disorders. Stockholm, Sweden: July 20-25, 2002.
67. Bauer M, Marseille DM, Geist CL, Van Herle K, **Rasgon NL**, Martinez D, Miller KJ, Haselrig T, Van Herle AJ, Czernin J, Phelps ME, Whybrow PC, Silverman DHS. “Effects of Thyroid Hormone Replacement Therapy on Regional Brain Metabolism.” Annual Meeting, Society of Nuclear Medicine. Los Angeles, CA: June 15-19, 2002. (Journal of Nuclear Medicine 2002; 43suppl:254P.)
68. Silverman DHS, Geist CL, Van Herle K, **Rasgon NL**, Martinez D, Miller KJ, Haselrig T, Van Herle A, Whybrow PC, Czernin J, Phelps ME, Bauer MJ. “Abnormal Regional Brain Metabolism in Patients with Hypothyroidism Secondary to Hashimoto’s Disease.” Annual Meeting, Society of Nuclear Medicine. Los Angeles, CA: June 15-19, 2002. (Journal of Nuclear Medicine 2002; 43suppl:254P.)
69. Binesh N, Bugbee M, Fairbanks L, **Rasgon NL**, Yue K, Han S, Davanzo P, Martin P, Guze B, Thomas MA. “Cerebral 2D L-COSY and Neuropsychological Correlates in Hepatic Encephalopathy.” Oral Presentation, 10th International Society of Magnetic Resonance in Medicine (ISMRM) Meeting. Honolulu, HI: May 18-24, 2002.
70. **Rasgon NL**, Altshuler LL, Elman S, Frye MA. “Increased Insulin Resistance in Women with Bipolar Disorder.” Annual Meeting, American Psychiatric Association. Philadelphia, PA: May 18-23, 2002.
71. **Rasgon NL**, Bauer M, Glenn T, Whybrow PC. “Gender Differences in Mood Patterns in Bipolar Disorder.“ Annual Meeting, American Psychiatric Association. Philadelphia, PA: May 18-23, 2002.
72. **Rasgon NL**, Altshuler LL, Fairbanks L, Dunkin J, Truong C, Brunhuber M, Rapkin A. “The Role of Estrogen Replacement Therapy on Mood and Cognition in Postmenopause.” Annual Meeting, Society of Biological Psychiatry. New Orleans, LA: May 16-18, 2002.
73. Bauer M, London E, **Rasgon N**, Berman S, Frye M, Mazziotta JC, Altshuler L, Whybrow PC. “Effects of Supraphysiological Doses of L-Thyroxine on Regional Brain Metabolism in Bipolar Disorder: Results of a FDG-PET Study.” Annual Meeting, American College of Neuropsychopharmacology (ACNP). Waikoloa, HI: December 9-13, 2001.
74. Sachs G, Altshuler L, Ketter T, Suppes P, **Rasgon N**, Frye M, Collins M. “Divalproex Versus Placebo for the Treatment of Bipolar Depression.” Annual Meeting, American College of Neuropsychopharmacology (ACNP). Waikoloa, HI: December 9-13, 2001.
75. Bauer M, London E, **Rasgon NL**, Altshuler L, Whybrow PC. “Deactivation of Limbic Regions During Treatment with Supraphysiological Thyroxine: A PET Study in Bipolar Disorder.” 7th World Congress of Biological Psychiatry. Berlin, Germany: July 1-6, 2001. (World J Biol Psychiatry 2001; 2 (suppl.1):355S.)
76. **Rasgon NL**, Small GW, Siddarth P, Miller K, Ercoli LM, Bookheimer SY, Lavretsky H, Huang SC, Barrio JR, Phelps ME. “Estrogen Use and Brain Metabolic Change in Older Adults.” Fifth International Symposium on Neurobiology and Neuroendocrinology of Aging. Bregenz, Austria: July 2001. (Experimental Gerontology 2001; 35(suppl.9-10):1426.)
77. **Rasgon NL**, Bauer M, Gyulai L, Glenn T, Whybrow PC. “Menstrual Cycle-Related Mood Changes in Women with Bipolar Disorder.” Fourth International Conference on Bipolar Disorder. Pittsburg, PA: June 2001. (Bipolar Disorders 2001; 3 (suppl.1):52.)
78. Bauer M, London ED, **Rasgon NL**, Berman S, Mandelkern M, Frye M, Mazziotta JJ, Altshuler L, Shinn AK, Gitlin M, Whybrow PC. “Effects of Supraphysiological Levothyroxine (T4) on Cerebral Glucose Metabolism in Bipolar Depression: Findings From a Positron Emission Tomographic Study.” Fourth International Conference on Bipolar Disorder. Pittsburgh, PA: June 14-16, 2001. (Bipolar Disorders 2001; 3 (suppl.1):25.)
79. Bauer M, London E, Berman S, **Rasgon N**, Mandelkern M, Frye MA, Altshuler LL. “Effects of Supraphysiological Thyroxine on Cerebral Glucose Metabolism in Bipolar Depression: A PET Study.” Annual Meeting, American Psychiatric Association. New Orleans, LA: May 5-10, 2001.
80. Rao RC, **Rasgon NL**, Hwang S, Altshuler LL, Zuckerbrow-Miller J, Korenman S. “Prevalence of Depression in Women with Polycystic Ovary Syndrome: Biological Correlates” Annual Meeting, American Psychiatric Association. New Orleans, LA: May 5-10, 2001.
81. **Rasgon NL**, Silverman D, Siddarth P, Lu C, Phelps M. “Gender Differences in the Sensitivity of Functional Neuroimaging in the Diagnosis of Alzheimer’s Disease.” Annual Meeting, American Psychiatric Association. New Orleans, LA: May 5-10, 2001.
82. Rao R, **Rasgon NL**, Hwang S, Altshuler LL, Zuckerbrow-Miller J, Korenman S. “Depression and PCOS: Rates and Correlates.” 3rd Annual Neuropsychiatry Today Conference. Maui, HI: March 29-April 1, 2001.
83. Rapkin A, **Rasgon NL**, Serra M, Biggio G, Mahesh V. “Neurosteroids and Menstrually-Related Disorders.” Second International Congress on Hormones, Brain, and Neuropsychopharmacology. Rhodes, Greece: July 15-19, 2000.
84. Miller K, Conney J, **Rasgon NL**, Fairbanks L, Small GW. “Effects of Estrogen on Cognition and Mood Functioning in Older Adults.” Proceedings and Abstracts, 5th Annual UCLA Research Conference on Aging. Los Angeles, CA: 2000.
85. **Rasgon NL**, Thomas MA, Guze B, Fairbanks L, Yue K, Curran J, Fawzy FI, Rapkin A. “Cerebral Metabolite Changes Across Women with PMDD.” Annual Meeting, Society of Biological Psychiatry. Chicago, IL: May 2000.
86. Suri R, Altshuler LL, **Rasgon NL**, Frye M, Gitlin M, Hwang S, Zuckerbrow-Miller J. “A Single-Blind Trial Assessing the Effectiveness/Efficacy of Fluoxetine Versus Sertraline for the Treatment of Major Depression.” Annual Meeting, American Psychiatric Association. Chicago, IL: May 13-18, 2000.
87. Yue K, **Rasgon NL**, Thomas MA, Guze B, Fairbanks L, Curran J, Rapkin A. “Cerebral Metabolite Changes Across the Menstrual Cycle in Women with PMDD and Controls: A Preliminary Report.” Poster presentation, International Society of Magnetic Resonance in Medicine. Denver, CO: April 2000.
88. **Rasgon NL**, Biggio G, Serra M, Tanavoli S, Rapkin AJ. “Neurosteroid Responses to L-Tryptophan Challenge Across the Menstrual Cycle in Women with PMDD and Controls.” European Congress of Psychosomatic Obstetrics and Gynecology Bergamo. Italy: June18-23, 1999.
89. **Rasgon NL**, Biggio G, Serra M, Tanavoli S, Rapkin AJ. “Serotonin-Induced Allopregnanolone Levels in Women with PMS.” Annual Meeting, American Psychiatric Association. Washington, DC: May 15-20, 1999.
90. Rapkin AJ, **Rasgon NL**, McGuire M.  “Neuroendocrine Response to IV L-Tryptophan Challenge in Premenstrual Syndrome.” Annual Meeting, Society for Gynecologic Investigation. Atlanta, GA: March 10-13, 1999.
91. **Rasgon NL**, Altshuler LL, Gudeman D, Burt V, Tanavoli S, Hendrick V, Korenman S. “Reproductive Health of Bipolar Women Taking Mood Stabilizers.” Congress of the International Society of Psychoneuroendocrinology. Trier, Germany: August 1-6, 1998.
92. **Rasgon NL**, McGuire MT, Tanavoli S, Fairbanks L, Rapkin AJ. “Serotonin Responses to an Intravenous L-Tryptophan Challenge Across the Menstrual Cycle in Women with Premenstrual Dysphoric Disorder and Controls.” 12th International Congress of the International Society of Psychosomatic Obstetrics and Gynecology. Washington, DC: June 20-23, 1998.
93. Broadway L, Dunkin J, **Rasgon NL**, Rapkin AJ, Altshuler LL. “The Effects of Estrogen Replacement Therapy on Cognitive Functions in Postmenopausal Women.” Third Annual UCLA Research Conference on Aging. Los Angeles, CA: June 1998.
94. Broadway L, Dunkin J, **Rasgon NL**, Altshuler L. “The Effects of Estrogen Replacement Therapy on Cognitive Functions in Postmenopausal Women.” Abstract, 3rd Annual UCLA Research Conference on Aging. Los Angeles, CA: 1998.
95. **Rasgon NL**. “Neuroendocrine Aspects of Cyclic Pelvic Pain: Possible Involvement of the Endogenous Opioid System.” 11th International Congress of Psychosomatic Obstetrics and Gynecology. Basel, Switzerland: 1995.
96. **Rasgon NL**. “Dysmenorrhea as an Emotional Stress.” 22nd Annual Symposium of the American Society of Psychosomatic Obstetrics and Gynecology. San Diego, CA: 1994.
97. **Luzina NL**, Bakuleva LP. “Possible Role of Alpha-Tocopherol in Decreasing Prostaglandin Synthesis in Dysmennorheic Patients.” 4th National Congress of Obstetrics and Gynecology. Mahachkala, U.S.S.R.: 1989.
98. **Luzina NL**, Yarigin KN. “Alpha-Tocopherol Influence on Antinociceptive System Regulation.” 4th National Congress of Pathophysiology. Kishinev, U.S.S.R.: 1989.
99. **Luzina NL**, Koslov AV, Osipov AN. “Exploration of Activation Mechanisms of Lipid Peroxidation Process in Patients with Cyclic Pain Syndromes.” 4th National Congress of Pathophysiology. Kishinev, U.S.S.R.: 1989.
100. **Luzina NL**, Bakuleva LP. “Utilization of L-Tocopherol in Endometriosis Therapy, Free Radicals and Biostabilizers.” Symposium. Sofia, U.S.S.R.: 1987.
101. **Luzina NL**, Rogkov SM. “Indications and Contraindications in the Utilization of Physical Medicine Methods in the Treatment of Gynecological Patients.” First National Scientific Conference of Physical Methods in Gynecology. Evpatoria, U.S.S.R.: 1983.
102. **Luzina NL**, Stojanov NG. “Treatment of Patients with Ovarian Dysfunction.” Scientific Conference of Physical Medicine. Odessa, U.S.S.R.: 1983.
103. **Luzina NL**, Grusina NA. “Difficulties in the Diagnosis of Systemic Lupus Erythematosis.” Scientific Conference on the Treatment of Internal Diseases. Odessa, U.S.S.R.: 1979.
104. **Luzina NL**, Dmitrieva EA. “Adrenal Function in Pelvic Inflammatory Disease.” Student Conference Report. Odessa, U.S.S.R: 1979.
105. **Luzina NL**. “Philosophical Problems of Consciousness and Unconsciousness.” Student Conference Report. Odessa, U.S.S.R.: 1978.
106. **Luzina NL**. “Characteristics of Liver and Myocardial Mitochondriasis II.” National Student Conference. Tbilisi, U.S.S.R.: 1978.
107. **Luzina NL**, Bojchenko IA. “Characteristics of Liver and Myocardial Mitochondrias.” Student Conference Report. Odessa, U.S.S.R.: 1977.
108. **Luzina NL**. “Physicians as Lenin’s Compatriots.” Student Conference Report. Odessa, U.S.S.R.: 1977.
109. **Luzina NL.**  “Vitamin Usage in the Treatment of Internal Diseases.” Student Conference Report. Odessa, U.S.S.R.: 1976.

**ARTICLES IN PEER-REVIEWED JOURNALS:**

1. Montano, CB, **Rasgon, NL,** & Herman, BK. Diagnosing binge eating disorder in a primary care setting. Postgraduate Medicine. 2016; 128(1): 115-23.
2. Holtzman, J, Miller, S, Hooshmand, F, Wang, PW, Chang, KD, Goffin, KC,…**Rasgon, N.** Gender by onset age interaction may characterize distinct phenotypic subgroups in bipolar disorder patients. Journal of Psychiatric Research. 2016; 76:128-35.
3. **Rasgon NL**, Watson-Lin, K, Epel, E, Blackburn, E, & Lin, J. Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: A preliminary study. Translational Psychiatry. 2016; 6: e709.
4. Robakis, TK, Williams, KE, Crowe, S, Watson, K, Gannon, J, & **Rasgon, NL**. Maternal attachment insecurity is a potent predictor of depressive symptoms in the early postnatal period. Journal of Affective Disorders. 2016; 190(5): 623-631.
5. Watson-Lin, K, Wroolie, TE, Robakis, T, & **Rasgon, NL**. Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response. Psychiatry Research. 2015; 230(3) 846-52.
6. Bauer, B, Glenn, T, Conell, T, Rasgon, N, Marsh, W, Sagduyu, K,,….Whybrow, PC. Common use of dietary supplements for bipolar disorder: A naturalistic, self-reported study. International Journal of Bipolar Disorders. 2015; 3:1-7
7. Robakis, TK, Holtzman, J, Stemmle, PG, Reynolds-May, MF, Kenna, HA, & **Rasgon, NL**. Lamotrigine and GABAA­ Receptor Modulators Interact with Menstrual Cycle Phase and Oral Contraceptives to Regulate Mood in Women with Bipolar Disorder. Journal of Affective Disorders. 2015; 175: 108-15.
8. Wroolie, TE, Kenna, HA, Watson, K, & **Rasgon, N.** Cognitive effects of hormone therapy continuation or discontinuation in a sample of women at risk for Alzheimer’s disease. American Journal of Geriatric Psychiatry. 2015; 23(11): 1117-26.
9. Holtzman, JN., Miller, S, Hooshmand, F, Wang, PW, Chang, KD, Hill, SJ, Rasgon, NL, & Ketter, TA. Childhood compared to adolescent onset bipolar disorder has more statistically significant clinical correlates. Journal of Affective Disorders. 2015: 179:114-120
10. Robakis, TK, Holtzman, J, Stemmle, PG, Reynolds-May, MF, Kenna, HA, & Rasgon, NL. Lamotrigine and GABA-A Receptor Modulators Interact with Menstrual Cycle Phase and Oral Contraceptives to Regulate Mood in Women with Bipolar Disorder. Journal of Affective Disorders. 2015: 175: 108-115
11. Bauer, M., Glenn, T., Alda, M., Andreassen, O. A., Angeloupoulos, E., Ardau, R…**Rasgon, N…**.et al. Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. European Psychiatry. 2015; 30(1)
12. Thompson DE, Kesler SR, Sudheimer K, Mehta KM, Thompson LW, Marquett RM… **Rasgon N**, et al. fMRI activation during executive function predicts response to cognitive behavioral therapy in older, depressed adults. American Journal of Geriatric Psychiatry. 2015; 23(1):13-22
13. Jacobs E.G., Epel ES, Lin J, Blackburn EH, **Rasgon NL.** Relationship between leukocyte telomere length, telomerase activity and hippocampal volume in early aging. JAMA Neurology 2014: 71(7):921-3
14. Wroolie TE, Kenna HA, Singh MK, **Rasgon NL**. Association between insulin resistance and cognition in patients with depressive disorders: Exploratory analyses into age-specific effects. Journal of Psychiatric Research. 2014; 60(2015): 65-72.
15. **Rasgon NL**, Kenna HA, Wroolie TE, Williams KE, DeMuth BN, Silverman DH. Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy. Psychiatry Research: Neuroimaging. 2014; 223(1): 28-36
16. **Rasgon NL**, Geist CL, Kenna HA, Wroolie TE, Williams KE, Silverman, DS. Prospective randomized trial to assess the effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PLOS ONE*.* 2014; 9(3): e89095
17. Bauer M, Glenn T, Alda M, Andreassen OA, Angelopoulos E, Ardau R, Baethge C….**Rasgon, N**….et al. Relationship between sunlight and the age of onset of bipolar I disorder: An international multisite study. Journal of Affective Disorders. 2014; 167:104-11.
18. Robakis TK, Williams KE, Crowe S, Kenna H, Gannon J, **Rasgon NL**. Optimistic outlook regarding maternity protects against depressive symptoms postpartum. Archives of Women’s Mental Health*.* 2014; 18(2): 197-208
19. Reynolds-May MF, Kenna HA, Marsh W, Stemmle PG, Wang P, Ketter TA, **Rasgon NL**. Evaluation of reproductive function in women treated for bipolar disorder compared to healthy controls. Bipolar Disorders. 2014: 16:37-47.
20. Ozerdem A, **Rasgon N**. Women with bipolar disorder: a lifetime challenge from diagnosis to treatment. Bipolar Disorders. 2014; 16(1):1-4.
21. Kenna HA, Reynolds-May M, Stepanenko A, Ketter TA, Hallmayer J, **Rasgon NL**. Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women. Journal of Affective Disorders. 2014; 156: 214-218.
22. Kenna HA, Tartter M, Hall SS, Lightbody AA, Nguyen Q, de Los Angeles CP, Reiss AL, **Rasgon NL**. High rates of comorbid depressive and anxiety disorders among women with premutation of the FMR1 gene. American Journal of Medical Genetics: Part B, Neuropsychiatric Genetics. 2013; 162(8) 872-878
23. Jacobs E, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, **Rasgon NL**. Accelerated cell aging in Female APOE-epsilon 4 Carriers: Implications for Hormone Therapy   
    Use. PLOS ONE. 2013; 8(2)
24. Miller S, Ittasakul P, Wang PW, Hill SJ, Childers ME, **Rasgon N**, Ketter TA. Enhanced zipirasidone combination therapy effectiveness in obese compared to nonobese patients with bipolar disorder. Journal of Clinical Psychopharmacology. 2012; 32(6): 814-819
25. Mason JS, Kenna HA, **Rasgon NL.** Insulin resistance in major depressive disorder and the effects of psychotropic medications. Clinical Practice. 2012; 9(5): 579-589.
26. [Kenna H](http://www.ncbi.nlm.nih.gov/pubmed?term=Kenna%20H%5BAuthor%5D&cauthor=true&cauthor_uid=22770543), [Hoeft F](http://www.ncbi.nlm.nih.gov/pubmed?term=Hoeft%20F%5BAuthor%5D&cauthor=true&cauthor_uid=22770543), [Kelley R](http://www.ncbi.nlm.nih.gov/pubmed?term=Kelley%20R%5BAuthor%5D&cauthor=true&cauthor_uid=22770543), [Wroolie T](http://www.ncbi.nlm.nih.gov/pubmed?term=Wroolie%20T%5BAuthor%5D&cauthor=true&cauthor_uid=22770543), [Demuth B](http://www.ncbi.nlm.nih.gov/pubmed?term=Demuth%20B%5BAuthor%5D&cauthor=true&cauthor_uid=22770543), [Reiss A](http://www.ncbi.nlm.nih.gov/pubmed?term=Reiss%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22770543), [**Rasgon N**](http://www.ncbi.nlm.nih.gov/pubmed?term=Rasgon%20N%5BAuthor%5D&cauthor=true&cauthor_uid=22770543), Fasting plasma insulin and the default mode network in women at risk for Alzheimer's disease. Neurobiology of Aging. 2012; 32(3): 641-649
27. Bauer M, Glenn T, Alda M, Andreassen OA, Ardau R, Bellivier F, Berk M,…, **Rasgon N**, et al. Impact of sunlight on the age of onset of bipolar disorder. Bipolar Disorders. 2012; 14(6): 654-663
28. **Rasgon NL**, Kenna HA, Wroolie TE, Kelley R, Silverman D, Brooks J, Williams KE, PowersBN, HallmayerJ, Reiss A. Insulin resistance and hippocamal

volume in women at risk for Alzheimer’s disease. Neurobiol Aging. 2011: 32(11)

1. Wroolie TE, Kenna HA, Williams KE, Powers BN, Holcomb M, Khaylis A, **Rasgon NL**. Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogen. American Journal of Geriatric Psychistry. 2011; 19(9): 792-802.
2. Vemuri M, Kenna HA, Wang PW, Ketter TA, **Rasgon NL**. Gender-specific lipid profiles in patients with bipolar disorder. Journal of Psychiatric Research. 2011; 45(8):1036-1041
3. Bauer M, Glenn T, **Rasgon N**, Marsh W, Sagduyu K, Grof P, Alda M, Murray G, Munoz R, Quiroz D, Bauer R, Jabs B, Whybrow PC. Decreasing the minimum length criterion for an episode of hypomania: evaluation using self-reported data from patients with bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience. 2011; 261(5): 341-347
4. Lin J, Kroenke CH, Epel E, Kenna HA, Wolkowitz OM, Blackburn E, **Rasgon NL.** Greater endogenous estrogen exposure is associated with longer telomeres in postmenopausal women at risk for cognitive decline. Brain Research. 2011; 1379: 224-31
5. Wang PW, Hill SJ, Childers ME, Chandler RA, **Rasgon, NL**, Ketter TA. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. Journal of Psychiatric Research. 2011; 45(8): 1128-1132
6. Williams KE, Stemmle PG, Westphal LM, **Rasgon NL**. Mood disorders in oocyte donor candidates: brief report and implications for future research. Human Reproduction. 2011; 26(4): 847-852
7. Holland JM, Thompson LW, Cucciare MA, Tsuda A, Okamura H, Spiegel D, **Rasgon N**, Gallagher-Thompson D. Cortisol outcomes among Caucasian and Latina/Hispanic women caring for a family member with dementia: A preliminary examination of psychosocial predictors and effects of a psychoeducational intervention. Stress and Health. 2011; 27(4): 334-346
8. Bauer M, Glenn T, **Rasgon N**, Marsh W, Sagduyu K, Munoz R, Schmid R, Haack S, Whybrow PC. Association between median family income and self-reported mood symptoms in bipolar disorder. Comprehensive Psychiatry. 2011; 52(1):17-25
9. Bauer M, Glenn T, **Rasgon N**, Marsh W, Sagduyu K, Munoz R, Lewitzka U, Schmid R, Whybrow PC. Association between age of onset and mood in bipolar disorder: Comparison of subgroups identified by cluster analysis and clinical observation. Journal of Psychiatric Research. 2010 ; 44(16): 1170-1175
10. Silverman DH, Geist CL, Kenna HA, Williams K, Wroolie T, Powers B, Brooks J,

**Rasgon NL**. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology. 2011; 36(4): 502-513

1. **Rasgon NL**, Kenna HA, Reynolds-May MF, Stemmle PG, Vemuri M, Marsh W, Wang P, Ketter TA. Metabolic dysfunction in women with bipolar disorder: the potential influence of family history of type 2 diabetes mellitus. Bipolar Disorders. 2010; 12(5): 91-98
2. McIntyre RS, Kenna HA, Nguyen H, Law C, Sultan F, Woldeyohannes H, Alsuwaidan M, Soczynska J, Adams AK, Cheng JS, Lourenco M, Kennedy SH, **Rasgon NL**. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Advances in Therapy. 2010; 27(2): 63-80
3. **Rasgon, N.L**., Kenna, H.A., Williams, K.E., Powers, B., Wroolie, T., and Schatzberg, A.F. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. The Scientific World Journal. 2010; 10: 321–328
4. **Rasgon NL**, Kenna HA, Wroolie TE, Kelley R, Silverman D, Brooks J, Williams KE, Powers BN, Hallmayer J, Reiss A. Insulin resistance and hippocampal volume in women at risk for Alzheimer’s disease. Neurobiology of Aging. 2011; 32(11): 1942-1948
5. Bauer M, Berman SM, Schiagenhauf F, Voytek B, **Rasgon N**, Mandelkern MA, Whybrow PC, London ED. Regional cerebral glucose metabolism and anxiety symptoms in bipolar depression: Effects of levothyroxine. Psychiatry Research-Neuroimaging. 2010; 181(1): 71-76
6. Morgan ML, Rapkin AJ, Biggio G, Serra M, Pisu MG, **Rasgon N**. Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women. Archives of Women’s Mental Health. 2010; 27(2): 63-80
7. Glenn T, Grof P, **Rasgon NL**, Marsh W, Sagduyu K, Alda M, Quiroz D, Whybrow PC, Bauer M. “Employment Status and Subsyndromal Symptoms in Bipolar Disorder”. Bipolar Disorders. 2009; 11: 43-43/.
8. Bauer M, Glenn T, Grof P, L **Rasgon NL**, Marsh W, Sagduyu K, Alda M, Murray G, Quiroz D, Malliaris Y, Sasse J, Whybrow PC.  Latitude, climate, season and self-reported mood in bipolar disorder. Bipolar Disorders. 2009; 11: 19-19.
9. Jiang B, Kenna H, **Rasgon N**. Genetic overlap between polycystic ovary syndrome and bipolar disorder: The endophenotype hypothesis. Medical Hypotheses. 2009; 73(6): 996-1004
10. Geist CL, Silverman DH, Kenna H, **Rasgon NL**. Verbal memory performance of postmenopausal women on estradiol therapy is positively correlated with regional brain metabolism in receptive language and auditory association areas. Journal of Nuclear Medicine*.* 2009; 50(S2):368.
11. Bauer M, Silverman DH, Schlagenhauf F, London ED, Geist CL, van Herle K, **Rasgon N**, Martinez D, Miller K, van Herle A, Berman SM, Phelps ME, Whybrow. Brain glucose metabolism in hypothyroidism:A Positron Emission Tomography Study Before and After Thyroid Hormone Replacement Therapy. Journal of Clinical Endocrinology and Metabolism. 2009; 94(8): 2922-2929
12. Bauer M, Glenn T, Grof P, **Rasgon NL**, Marsh W, Sagduyu K, Alda M, Lewitzka U,  Schmid R, Whybrow PC. Relationship between adjunctive medications for anxiety and time spent ill in patients with bipolar disorder. International Journal of Psychiatry in Clinical Practice. 2009; 13(1): 70-77
13. Kenna, H., Jiang, B., & **Rasgon, N.L**. Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harvard Review of Psychiatry. 2009; 17(2): 138-46.
14. McIntyre RS, **Rasgon NL**, Kemp DE, Nguyen HT, Law CW, Taylor V, Woldeyohannes HO, Alsuwaidan MT, Soczynska JK, Kim B, Lourenco MT, Kahn LS, Goldstein BI. Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap. Current Diabetes Reports. 2009; 9(1):51-9.
15. Marsh W, Ketter T, **Rasgon N**. increased depressive symptoms in postmenopausal age women with bipolar disorder: age and gender comparison. Journal of Psychiatric Research. 2009; 43(8): 798-802.
16. Bauer M, Glenn T, Grof P, **Rasgon N**, Alda M, Marsh W, Sagduyu K, Schmid R,  
    Adli M, Whybrow PC.  Comparison of sleep/wake parameters for self-monitoring  
    bipolar disorder.  Journal of Affective Disorders. 2009; 116(3): 170-175
17. Bauer M, Glenn T, Grof P, **Rasgon N**, Marsh W, Sagduyu K, Alda M, Murray G, Quiroz D, Malliaris Y, Sasse J, Pilhatsch M, Whybrow PC. Relationship among latitude, climate, season and self-reported mood in bipolar disorder. Journal of Affective Disorders. 2009; 116(1-2): 152-57.
18. Kenna, H., **Rasgon, N**., Geist, C., Small, G. & Silverman, D. Thalamo-basal ganglia connectivity in postmenopausal women receiving estrogen therapy. Neurochemical Research. 2009; 34(2): 234-7
19. Bauer M, Glenn T, Grof P, **Rasgon NL**, Marsh W, Sagduyu K, Alda M, Lewitzka U,  
    Sasse J, Kozuch-Krolik E, Whybrow PC.  Frequency of subsyndromal symptoms  
    and employment status in patients with bipolar disorder.  Social Psychiatry and Psychiatric Epidemiology. 2009; 44(7): 515-22
20. **Rasgon NL**, Kenna HA, Geist C, Small G, Silverman D. Cerebral metabolic patterns in untreated postmenopausal women with major depressive disorder. American Journal of Geriatric Society. 2008; 164(1): 77-80
21. Wroolie TE, Kenna HA, Williams KE, Powers BN, Holcomb M, Lazzeroni L, **Rasgon NL**. Cognitive effects of memantine in postmenopausal women at-risk for dementia: a pilot study. Acta Psychiatrica Scandinavica. 2009; 119(3): 172-9.
22. Bauer M, Wilson T, Neuhaus K, Sasse J, Pfennig A, Lewitzka U, Grof P, Glenn T, **Rasgon N**, Bschor T, Whybrow PC. Self-reporting software for bipolar disorder: validation of ChronoRecord by patients with mania. Psychiatry Research. 2008; 159(3): 359-66
23. **Rasgon N**, Kenna H, Geist C, Powers B, Wroolie T, Williams K, Silverman D. Regional cerebral metabolism and neuropsychological performance among healthy postmenopausal users of estrogen therapy. Biological Psychiatry. 2008; 63(7): 16S-16S.
24. Bauer M, Glenn T, Whybrow PC, Grof P, **Rasgon N**, Alda M, March W, Sagduyu K, Schmid R, Adli M. Changes in self-reported sleep duration predict mood changes in bipolar disorder. Psychological Medicine. 2008; 38(7): 1069-72.
25. Jarvik L, LaRue A, Blacker D, Gatz M, Kawas C, McArdie JJ, Morris JC, Mortimer JA, Ringman JM, Ercoli L, Freimer N, Gokhman I, Manly JJ, Plassman BL, **Rasgon N**, Roberts JS, Sunderland T, Swan GE, Wolf PA, Zonderman AB. Children of persons with Alzheimer disease: what does the future hold? Alzheimer Disease & Associated Disorders. 2008; 22(1): 6-20
26. Bauer M, Kozuch E,Glenn T, Grof P, Guztmann C, Kiermeir J, Nuehaus K, **Rasgon N**, Ricken R, Sasse J, Schmid, Whybrow PC. Die elektronische erfassung des longitudinalen verlaufs bipolarer storungen. Nervenheilkunde. 2008; 27: 165-172.
27. Marsh WK, Templeton A, Ketter TA, **Rasgon NL**. Increased frequency of depressive episodes during the menopausal transition in women with bipolar disorder: Preliminary report. Journal of Psychiatric Research. 2008; 42(3): 247-51
28. Ballagh SA, **Rasgon NL**, Moore AA. Management of vasomotor symptoms during the menopausal transition. Supplement to The Journal of Family Practice. 2008 Jan; 57(1).
29. Williams K, Marsh W, **Rasgon N**. Mood disorders and fertility in women: A critical review of the literature and implications for future research. Human Reproduction. 2007; 13(6): 607-16.
30. Miller KJ, Parsons TD, Whybrow PC, Van Herle K, **Rasgon N**, Van Herle A, Martinez D, Silverman D, Bauer M. Verbal memory retrieval deficits associated with untreated hypothyroidism. Journal of Neuropsychiatry and Clinical Neurosciences. 2007; 19 (2): 132-6
31. Zappert LN, **Rasgon NL**. Biological and psychosocial correlates of perimenopausal depression: Implications for treatment. Depression: Mind and Body. 2007; 3(2).
32. **Rasgon NL**, Kenna HA, Wong M, Whybrow PC, Bauer M. Hypothalamic-pituitary-end organ function in women with bipolar depression. Psychoneuroendocrinology. 2007; 32(3): 279-86.
33. Reynolds M, Sisk EC, **Rasgon N**. Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. Current Medicinal Chemistry. 2007; 14(26): 2799-812.
34. Bauer M, Grof P,Glenn T, **Rasgon NL**, Sasse J, Whybrow PC. “Self-Reported Depression and Minimum Length of Depression Episodes in Bipolar Disorder”. Bipolar Disorders. 2007; 9: 19-19.
35. Vemuri M, **Rasgon N**. Diagnosing and treating bipolar disorder in women of reproductive age. Continuing Medical Education. Feb; 2007.
36. **Rasgon N**, Dunkin J, Fairbanks L, Altshuler LL, Trunog C, Elman S, Wroolie TE, Brunhuber MV, Rapkin A. Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. Journal of Psychiatric Research. 2007; 41(3-4):338-43
37. Bauer M, Glenn T, Grof P, Pfenning A**, Rasgon NL**, Marsh W, Munoz RA, Sagduyu K, Alda M, Quiroz D, Sasse J, Whybrow PC. Self-reported data from patients with bipolar disorder: Frequency of brief depression. Journal of Affective Disorder. 2007; 101(1-3): 227-233
38. Binesh N, Huda A, Thomas MA, Wyckoff N, Bugbee M, Han S, **Rasgon N**, Davanzo P, Sayre J, Guze B, Martin P, Fawzy F. Hepatic encephalopathy: a neurochemical, neuroanatomical, and neuropsychological study. Journal of Applied Clinical Medical Physics. 2006; 7(1): 86-96.
39. Zappert LN, **Rasgon NL**. Reproductive function in women diagnosed with bipolar disorder. Women’s Health in Psychiatry. 2006.
40. Bauer M, Grof P, **Rasgon N**, Glenn T, Alda M, Priebe S, Ricken R, Whybrow PC. Mood charting and technology: New approach to monitoring patients with mood disorders. Current Psychiatry Reviews. 2006; 2(4): 423-429.
41. Dunkin J, **Rasgon N**, Zeller M, Wagner-Steh K, David S, Altshuler L, Rapkin A. Estrogen replacement and cognition in postmenopausal women: Effects of years since menopause on response to treatment. Drug Development Research. 2006; 66: 150-159.
42. Bauer M, Grof P, **Rasgon NL**, Marsh W, Munoz RA, Sagduyu K, Alda M, Quiroz D, Glenn T, Barthge C, Whybrow PC. Do antidepressants influence mood patterns? A naturalistic study in bipolar disorder. European Psychiatry. 2006; 21: 262-269.
43. Bauer M, Grof P, **Rasgon NL**, Marsh W, Munoz RA, Sagduyu K, Alda M, Quiroz D, Glenn T, Barthge C, Whybrow PC. Self-reported data from pateinets with bipolar disorder: Impact on minimum episode length for hypomania. Journal of Affective Disorders. 2006; 96(1-2): 101-5.
44. Glenn T, Whybrow PC, **Rasgon NL**, Grof P, Alda M, Barthge C, Bauer M. Approximate entropy of self-reported mood prior to episodes in bipolar disorder. Bipolar Disorders. 2006; 8(5 p1): 424-9.
45. Miller KJ, Parsons TD, Whybrow PC, Van Herle K, **Rasgon N**, Van Herle A, Martinez D, Silverman D, Bauer M. Memory improvement with treatment of hypothyrodism. The International Journal of Neuroscience. 2006; 116(8): 895-906.
46. Wroolie T, Williams KE, Keller J, Zappert L, Shelton SD, Kenna HA, Reynolds MF, **Rasgon NL**. Mood and neuropsychological changes in women with mid-life depression treated with escitalopram. Journal of Clinical Psychopharmacology. 2006; 26(4): 361-6.
47. Glenn, T., Bauer, M., Grof, P., **Rasgon, N**., & Whybrow, P. C. Improving symptom monitoring-using technology to explore the course of bipolar disorder.Bipolar Disorders. 2006; 8:13-31.
48. **Rasgon NL**, Geist Cl, Phelps ME, Silverman DHS. Changes in regional brain metabolism and insulin resistance in postmenopausal women. Journal of Nuclear Medicine. 2006; 47(S1): 300P.
49. Suppes T, Morrell MJ, **Rasgon N**, Cohen LS, Viguera AC. Reproductive health and bipolar disorder. CNS Spectrums. 2006 May.
50. Bauer M, Grof P, **Rasgon N**, Bschor T, Glenn T, Whybrow PC. Temporal relation between sleep and mood in patients with bipolar disorder. Bipolar Disorders. 2006; 8:160-167.
51. Adli M, Whybrow PC, Grof P, **Rasgon N**, Gyulai L, Baethge C, Glenn T, Bauer M. Use of polypharmacy and self-report mood in outpatients with bipolar disorder. International Journal of Psychiatry in Clinical Practice. 2005; 9(4): 251-256.
52. Masand PS, Culpepper L, Henderson D, Lee S, Littrell K, Newcomer JW, **Rasgon N**. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to atypical antipsychotic utilization. CNS Spectrums. 2005; 10(10):suppl 14:1-15.
53. Culpepper L, Henderson D, Lee S, Littrell K, Newcomer JW, **Rasgon N**. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to atypical antipsychotic utilization. Primary Psychiatry. 2005; 12(10):1-15.
54. Marsh WK, Zappert LN, Williams EK, Templeton AJ, Reynolds MF, Ketter TA, **Rasgon NL**. “Clinical Course of Bipolar Disorder During Pregnancy in Women Receiving Minimal or No Prescription Psychotropic Medication.” Bipolar Disorders. 2005; 7: 75-76.
55. Zappert L, Glenn T, Bauer M, Elman S, Frye M, Altshuler L, Gitlin M, Marsh W, Reynolds M, Kenna H, Templeton A, Shelton S, **Rasgon N**. “Effects of Gender on Mood in the Clinical Course of Bipolar Disorder.” Bipolar Disorders. 2005; 7:115-115.
56. **Rasgon NL**, Kenna HA. Insulin resistance in depressive disorders and Alzheimer’s disease: revisiting the missing link hypothesis. Neurobiology of Aging. 2005; 26(S1): 103-7.
57. **Rasgon NL**, Reynolds MF, Saad M, Elmann S, Frye MA, Bauer M, Altshuler LL. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. Journal of Affective Disorders. 2005; 89(1-3): 217-25.
58. Bauer M, **Rasgon N**, Grof P, Gyulai L, Glenn T, Whybrow PC.Does the use of an automated tool for self-reporting mood by patients with bipolar disorder bias the collected data? Medscape General Medicine. 2005; 7(3): 21.
59. Jarvik LF, La Rue A, Gokhman I, Harrison T, Holt L, Steh B, Harker J, Larson S, Yaralian P, Matsuyama S, **Rasgon N**, Geschwind D, Freimer N, Jimenez E, Schaeffer J. Middle-aged children of Alzheimer parents, a pilot study: stable neurocognitive performance at 20-year follow-up. Journal of Geriatric Psychiatry and Neurology. 2005; 18(4): 187-191.
60. Templeton A, **Rasgon N**. Gender differences in bipolar disorder. Bipolar Case Review Quarterly. 2005; 1:3-6.
61. **Rasgon NL**, Magnusson C, Johansson AL, Pedersen NL, Elman S, Gatz M. Endogenous and exogenous hormone exposure and risk of cognitive impairment in Swedish twins: a preliminary study. Psychoneuroendocrinology. 2005; 30(6): 558-67.
62. **Rasgon N**, Shelton S, Halbreich U. Perimenopausal mental disorders – epidemiology and phenomenology. CNS Spectrums. 2005; 10(6): 471-8.
63. **Rasgon NL**, Altshuler LL, Fairbanks L, Elman S, Bitran J, Labarca R, Saad M, Kupka R, Nolen WA, Frye MA, Suppes T, McElroy SL, Keck PE Jr., Leverich G, Grunze H, Walden J, Post R, Mintz J. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disorders. 2005; 7(3): 246-59.
64. Reynolds M, **Rasgon N**, Elman S, Saad M, Frye M, Bauer M, Altshuler L, Marsh W. Prospective longitudinal endocrine study of women treated for bipolar disorder. Bipolar Disorders. 2005; 7:90-90.
65. Dunkin J, **Rasgon N**, Wagner-Steh K, David S, Altshuler L, Rapkin A. Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women. Psychoneuroendocrinology. 2005; 30(3): 284-96.
66. Binesh N, Huda A, Bugbee M, Gupta R, **Rasgon N**, Kumar A, Green M, Han S, Thomas MA. Adding another spectral dimension to 1H magnetic resonance spectroscopy of hepatic encephalopathy. Journal of Magnetic Resonance Imaging. 2005; 21(4): 398-405.
67. Bauer M, Grof P, **Rasgon N**, Sasse J, Glenn T, Neuhaus K, Gutzmann C, Whybrow PC. New technology for longitudinal studies of patients with bipolar disorder. Clinical Approaches in Bipolar Disorders. 2005;4(1):4-10.
68. Bauer M, London ED, **Rasgon N**, Berman SM, Frye MA, Altshuler LL, Mandelkern MA, Bramen J, Voytek B, Woods R, Mazziotta JC, Whybrow PC. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Molecular Psychiatry. 2005; 22: 1-14.
69. **Rasgon NL**, Silverman D, Siddarth P, Miller K, Ercoli LM, Elman S, Lavretsky H, Huang SC, Phelps ME, Small GW. Estrogen use and brain metabolic change in postmenopausal women. Neurobiology of Aging. 2005; 26(2): 229-35.
70. **Rasgon N**, Bauer M, Grof P, Gyulai L, Elman S, Glenn T, Whybrow PC. Sex-specific self-reported mood changes by patients with bipolar disorder. Journal of Psychiatric Research. 2005; 39(1): 77-83.
71. Bauer M, **Rasgon N**, Grof P, Altshuler L, Gyulai L, Lapp M, Glenn T, Whybrow PC. Mood changes related to antidepressants: a longitudinal study of patients with bipolar disorder in a naturalistic setting. Psychiatry Research. 2005; 133(1): 73-80.
72. Bauer M, Fairbanks L, Berghöfer A, Hierholzer J, Bschor T, Baethge C, **Rasgon N**, Sasse J, Whybrow PC. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. Journal of Affective Disorders. 2004; 83(2-3): 183-190.
73. Becker OV, **Rasgon NL**, Marsh WK, Glenn T, Ketter TA. Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report. Bipolar Disorders. 2004; 6(5): 435-9.
74. Jarvik LF, Harrison TR, Holt L, Jimenez E, Larson SW, LaRue A, Matsuyama SS, **Rasgon N**, Schaeffer J, Steh B, Yaralian P. Children of Alzheimer patients: more data needed. Journals of Gerontology Series A- Biological Sciences and Medical Sciences. 2004; 59(10): 1076-7.
75. Suri R, Altshuler L, Hendrick V, **Rasgon N**, Lee E, Mintz J. The impact of depression and fluoxetine treatment on obstetrical outcome. Archives of Women’s Mental Health. 2004; 7 (3): 193-200.
76. **Rasgon N**. The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence. Journal of Clinical Psychopharmacology. 2004; 24(3): 322-34.
77. Bauer M, Grof P, Gyulai L, **Rasgon N**, Glenn T, Whybrow PC. Using technology to improve longitudinal studies: self-reporting with ChronoRecord in bipolar disorder. Bipolar Disorders. 2004; 6(1): 67-74.
78. Burt V, & **Rasgon N**. Special considerations in treating bipolar disorder in women. Bipolar Disorders. 2004; 6(1): 2-13.
79. **Rasgon N**, Jarvik L. Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. Journals of Gerontology Series A- Biological Sciences and Medical Sciences. 2004; 59(2): 178-83.
80. Trendelenburg M, Sasse J, Schlosser T, Whybrow P, Grof P, Gyulai L, **Rasgon N**, Glenn T, Bschor T, Bauer M. “Using Software to Improve Longitudinal Studies: Self-Reporting with ChronoRecord in Bipolar Disorder.” Acta Psychiatrica Scandinavica 2003; 423(110):39-40.
81. **Rasgon NL**, Garfinkel A, Pamfry L, Elman S, Prolo P, Negrao AB, Licinio J. Emergent oscillations in a mathematical model of the human menstrual cycle. CNS Spectrums. 2003; 8(11): 805-14.
82. Whybrow PC, Grof P, Gyulai L, **Rasgon N**, Glenn T, Bauer M. The electronic assessment of the longitudinal course of bipolar disorder: the ChronoRecord (R) software. Pharmacopsychiatry. 2003; 36: S244-249.
83. Bauer M, London E, Silverman D, **Rasgon NL**, Kirchheiner J, Whybrow P. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry. 2003; 36(274): 1-6, S215-221.
84. **RasgonNL**, BauerM, Glenn T, ElmanS, Whybrow PC. Menstrual cycle-related mood changes in women with bipolar disorder. Bipolar Disorders. 2003; 5:48-52.
85. **Rasgon NL**, Rao R, Elman S, Zuckerbrow-Miller J, Altshuler LL, Korenman S. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. Journal of Affective Disorders. 2003; 74:299-304.
86. Bauer M, Adli M, Bschor T, Heinz A, **Rasgon N**, Frye M, Grunze H, Kupka R, Whybrow PC. Clinical applications of levothyroxine in refractory mood disorders. Clinical Approaches in Bipolar Disorders. 2003; 2:49-56.
87. **Rasgon NL**, Bauer M, Grof P, Gyulai L, Elman S, Glenn T, Whybrow PC. Prospective studies of bipolar disorder: Influence of gender. 2003.
88. **Rasgon NL**, Bauer M, Glenn T, Elman S, Whybrow PC. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disorders. 2003; 5: 48-52.
89. Miller KJ, Conney JC, **Rasgon NL**, Fairbanks LA, Small GW. Mood symptoms and cognitive performance in women estrogen users and nonusers and men. Journal of American Geriatric Society. 2002; 50(11): 1826-30.
90. Rapkin A, Mikacich J, **Rasgon NL**. The clinical nature and formal diagnosis of premenstrual, postpartum, and perimenopausal affective disorders. Current Psychiatry Reports. 2002; 4(6): 419-428.
91. **Rasgon NL**, Elman S. Special considerations in women with bipolar disorder. Directions in Psychiatry. 2002; 22:259-269.
92. **Rasgon NL**, Carter MS, Elman S, Bauer M, Love M, Korenman SG. Common treatment of polycystic ovarian syndrome & major depressive disorder: case report and review. Current Drug Targets-Immune, Endocrine, & Metabolic Disorders. 2002; 2(1): 97-102.
93. **Rasgon NL**, Altshuler LL, Fairbanks L, Dunkin J, Davtyan C, Elman S, Rapkin A. Estrogen replacement therapy in the treatment of major depression in perimenopausal women. Journal of Clinical Psychiatry. 2002; 63(S7): 45-48.
94. **Rasgon NL**, Small GW, Siddarth P, Miller K, Ercoli LM, Bookheimer SY, Lavretsky H, Huang SC, Barrio J, Phelps ME. Estrogen use and brain metabolic change in older adults: a preliminary report. Psychiatric Research: Neuroimaging. 2001; 107(1): 11-18.
95. **Rasgon NL**, Serra M, Biggio G, Pizu G, Fairbanks L, Rapkin A. Neuroactive steroid-sertonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome. European Journal of Endocrinology. 2001; 145(1): 25-33.
96. **Rasgon NL**, Thomas A, Guze B, Fairbanks L, Yue K, Curran J, Rapkin AJ. Menstrual cycle-related brain metabolite changes using 1H-MR spectroscopy in premenopausal women: a pilot study. Psychiatric Research: Neuroimaging. 2001; 106: 47-57.
97. Suri R, Altshuler LL, **Rasgon NL**, Calcagno J, Frye MA, Gitlin M, Hwang S, Zuckerbrow-Miller J. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. Journal of Clinical Psychiatry. 2000; 61(12):942-6.
98. Small GW, Ercoli LM, Silverman D, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, **Rasgon NL**, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(11): 6037-6042.
99. **Rasgon NL**, Altshuler LL, Gudeman D, Burt VK, Tanavoli S, Hendrick V, Korenman S. Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report. Journal of Clinical Psychiatry. 2000; 61(3): 173-178.
100. **Rasgon NL**, McGuire MT, Tanavoli S, Fairbanks L, Rapkin AJ. Neuroendocrine response to an IV L-tryptophan challenge across the menstrual cycle in women with premenstrual dysphoric disorder and controls. Fertility and Sterility. 2000; 73(1):144-149.
101. **Rasgon NL**, Nonacs R. Toward optimal health: the experts respond to depression (Interview by Jodi Godfrey Meisler). Journal of Women’s Health & Gender-Based Medicine. 1999; 8(9): 1141-1146.
102. Burt VK, Altshuler LL, **Rasgon NL**. Depressive symptoms in the perimenopause: prevalence, assessment and guidelines for treatment. Harvard Review of Psychiatry. 1998; 6: 121-132.
103. **Rasgon NL**, Ananth J, Mena A, Krout B, Boone K. Agenesis of corpus callosum and dementia of the Alzheimer’s type: a review and case report. Canadian Journal of Psychiatry. 1994; 39(7): 429-432.
104. Kryzhanovskii GN, **Luzina NL**, Yarigin KN. Alpha-tocopherol-induced activation of the endogenous opioid system. Bulletin of Experimental Biology and Medicine. 1989; 107:566-567.
105. Gulyaeva NG, Luzina NL, Levshina IP, Kryzhanovskii GN. Stage of inhibition of lipid peroxidation during stress. Bulletin of Experimental Biology and Medicine. 1988; 106:1684-1688.
106. **Luzina NL**. Antioxidant treatment of dysmenorrhea as a pathogenetic method of therapy. New Scientific Approaches in Gynecology. 1988:108-112.
107. **Luzina NL**, Bakuleva LP. Dysmenorrhea: etiology, pathogenesis and therapy, review. Kasanskii Medical Journal. 1988; 3:211-214.
108. Kryzhanovskii GN, Bakuleva LP, **Luzina NL**, Vinogradov VA, Yarigin KN, Kubatiev AA. Role of the endogenous opioid system in the analgesic effect of L-tocopherol in dysmenorrhea. Bulletin of Experimental Biology and Medicine. 1988; 105(2): 162-164.
109. **Luzina NL**. Dysmenorrhea as a clinical example of emotional-painful stress. Modern Problems of Homeostasis. 1987:184-185.
110. **Luzina NL**, Bakuleva LP. The use of antioxidant L-tocopherol acetate in the treatment of dysmenorrhea. Acusherstvo i Gynecologia. 1987; 5: 67-69.
111. **Luzina NL**. Relationship of physical treatment side effects to various degrees of ovarian hypofunction. Curortologia i Physiotherapia. 1986; 19:67-69.
112. **Luzina NL**, Zelinski AA, Kryzhanovskii GN. Peculiarities of the gynecological patient’s reaction during the physical medicine stage of rehabilitation. Acusherstvo i Gynecologia 1986;11:68-71.
113. **Luzina NL,** Zelinskii AA, Kryzhanovskii GN. Body reactivity characteristics of chronic salpingo-oophoritis patients at the health resort stage of rehabilitation. Acusherstvo i Gynecologia. 1986; 69-71.
114. **Luzina NL**. Utilization of vibrotherapy in the treatment of gynecological patients. Vibrotherapia. 1985; 107-109.
115. **Luzina NL**. Prevention of side effects during the physical treatment of pelvic inflammatory disease. Curortologia i Physiotherapia. 1984; 17:105-107.

**ARTICLES SUBMITTED:**

1. Balzafiore, DR, **Rasgon, NL**, Yuen, LD, Shah, S, Kim, H, Goffin, KC,…Ketter, TA. Lifetime eating disorder comorbidity associated with delayed depressive recovery in bipolar disorder. Manuscript submitted to the Journal of Affective Disorders.
2. Sabbagh, MN,Schäuble B, Anand, K,Richards D, Beach TG, Murayama S,…**Rasgon, N**,… Seibyl, J. Barrel Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimer’s disease. Neurology
3. Mansur, R, **Rasgon, N**, Yena, L, Zhou, A, Rosenblat, J, Bruins, R,…McIntyre, R. Determinants of cognitive function in adults with Type 2 Diabetes Mellitus: A meta-analyis. Journal of the International Neuropsychological Society
4. Awaad, R, Fisher, AJ, & **Rasgon, NL**. Development and validation of the Muslims’ Perceptions and Attitudes to Mental Health (M-PAMH) Scale. Journal of Epidemiology and Psychiatric Sciences
5. Williams KE, Stemmle PG, Casper RC, Cox TA, **Rasgon NL**. Predictors of Treatment Response in Postpartum Depression: A Chart Review Study.

**ARTICLES IN PREPARATION:**

1. Wroolie, T, Watson-Lin, Chen, K, & **Rasgon, NL**. Relationship between metabolic markers and cognition in adults at risk for Alzheimer’s disease. Manuscript in preparation.
2. **Rasgon, N**., Wroolie, T., Watson Lin, K., & Robakis, T. Childhood trauma and leukocyte telomere length. Manuscript in preparation.
3. Watson Lin, K., Williams, K., & **Rasgon, N.** Review of inflammatory biomarkers. Manuscript in preparation.
4. Wroolie, T., Robakis, T., Watson Lin, K., & **Rasgon, N**. Childhood trauma, insulin resistance, and cognition. Manuscript in preparation.
5. Robakis, T., Wroolie, T., Watson Lin, K., & **Rasgon, N**. Childhood trauma as predictor of response to antidepressant response. Manuscript in preparation.
6. Wroolie, T., Chen, K., Sonni, I., Balzafiore, D., **Rasgon, N**. Magnesium L-threonate for the enhancement of memory and learning in patients with mild to moderate dementia. Manuscript in preparation.
7. McDivitt, DS, Wroolie, T, Roat-Shumway, S, Balzafiore, DR, Watson, KT, & **Rasgon, NL**. Does childhood maltreatment influence the biology of the female reproductive life cycle? Manuscript in preparation

**NON-PEER REVIEWED ARTICLES:**

1. **Rasgon N.** & Nemeroff, CB. Comment. More time for science and less time for administration? Neuropsychopharmacology. 2016; Advance online publication
2. Wroolie T, **Rasgon N**. Comment. [Review of JAMA 2008 article Sildenafil improves adverse sexual effects from antidepressants in women]. North American Menopause Society *First to Know*. September 17, 2008; 6-7.
3. **Rasgon N**, Elman S. When not to treat depression in PCOS with antidepressants. Current Psychiatry. 2005 Feb; 4(2):47-60.
4. **Rasgon NL**. Anatomic, functional, and clinical studies of neuroendocrine function in bipolar disorder. Advanced Studies in Medicine. 2003; 3(8A):S726-S732.
5. **Rasgon NL**, Harden C. Neuroendocrine function in women with epilepsy or bipolar disorder: implications for patient management. Advanced Studies in Medicine. 2003; 3(8A):S740-S744.

**LETTERS TO THE EDITOR (Peer Reviewed):**

1. Stemmle PG, Kenna HA, Wang PW, Hill SJ, Ketter TA, **Rasgon NL**. Insulin Resistance and Hyperlipidemia in Untreated Women with Bipolar Disorder. Journal of Psychiatric Research. 2008; 43(3): 341-3
2. Bauer M, Glenn T, Whybrow PC, Grof P, **Rasgon N**, Alda M, Marsh W, Sagduyu K, Schmid R, Aldi M. Changes in self-reported sleep duration predict mood changes in bipolar disorder. Psychological Medicine. 2008; 38:1-3.
3. Vemuri M, **Rasgon N**. A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain. Journal of Clinical Psychiatry. 2007; 68(12): 1989
4. **Rasgon NL**, Jarvik L.Cannon-Spoor et al.’s assessment. American Journal of Geriatric Psychiatry. 2006; 14(3): 293.
5. **Rasgon NL**, Yarygin KN. Vitamin E for the treatment of dysmenorrhea. British Journal of Gynaecology. 2005; 112(8): 150-9.
6. Jarvik L, Harrison T, Holt L, Jimenez E, Larson SW, LaRue A, Matsuyama SSS, **Rasgon N**, Schaeffer J, Steh B, Yaralian P. Children of Alzheimer patients: more data needed. Journal of Gerontology: Medical Sciences. 2004; 59(10):1076-7.
7. **Rasgon NL**, Altshuler L, Fairbanks L. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. Menopause Digest. 2003;15(2):8-
8. **Rasgon NL**. Fluoxetine shows modest efficacy relieving hot flashes: Commentary on

[Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA](http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11896107&dopt=Abstract) (Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol2002 Mar; 6:1578-1583). North American Menopause Society News. 2002 May.

1. **Rasgon NL**, Altshuler LL, Fairbanks L. Estrogen replacement therapy (ERT) for depression. American Journal of Psychiatry. 2001; 158(10): 1738.
2. **Rasgon NL**, Jarvik GP, Jarvik LF. Affective disorders and Alzheimer’s disease: a missing link hypothesis. The American Journal of Geriatric Psychiatry. 2001; 9(4):444.

**MONOGRAPHS:**

1. **Rasgon N**. Differential Effects of Antieileptic Drugs on Reproductive Function in Women with Mood Disorder. In Stowe ZN, Herzog AG, et al, *The Use of Antiepileptic Drugs Long-term Management Issues*. 2007.
2. **Rasgon N**, Ketter T, Chang K. Physicians' Information and Education Resource (PIER): Update in *Bipolar Disorders*, 2006.
3. **Rasgon, NL**.  Antipsychotics 2006: Cost-Conscious Usage.  In Glick, ID, Balon, R, Zisook, S, et al., *ASCP Model Psychopharmacology Curriculum, 4th Edition*, American Society of Clinical Psychopharmacology, Glen Oaks, NY, 2006.
4. **Rasgon NL**. *Polycystic Ovary Syndrome: Characteristics and Clinical Controve*r*sies*. 2002 (December): 1-62.
5. Altshuler LL, Cohen LS, Moline ML, **Rasgon NL** et al. The expert consensus guideline series: treatment of depression in women 2001. Postgraduate Medicine Special Report. 2001 (March): 1-116.
6. **Luzina NL**. Antioxidant Therapy in Dysmenorrhea Treatment Complex. Ph.D. Thesis. Moscow, U.S.S.R.. 1988: 1-129.

**INVITED BOOKS:**

1. **Rasgon, NL**. *Insulin Resistance and Metabolic Syndrome in Neuropsychiatry*. Informa Press, April 2008.
2. **Rasgon NL** (Ed).  *Estrogen’s Effects in the Central Nervous System: Estrogen and Mood.  Estrogen’s Effects on Brain Function – What’s Next?* John Hopkins Press, January 2006.

**BOOK CHAPTERS BY INVITATION:**

1. Balzafiore, DR, Borish, S, Budhan, V, & **Rasgon, NL**. The treatment of bipolar disorder in women. In E. Vieta & AF Carvalho (Eds.) *The Treatment of Bipolar Disorder: Integrative Clinical Strategies and Future Directions* (Manuscript submitted)
2. **Rasgon NL**, Williams, K, Hendrick VC, Garrick TR. Endocrine and metabolic disorders. In BJ Sadock, VA Sadock, P Ruiz (eds): Kaplan & Sadock's Comprehensive Textbook of Psychiatry (10th ed). (Manuscript Submitted)
3. Kenna, H., Wroolie, T., Balzafiore, D., & **Rasgon, N. L**. Insulin resistance and implications for hippocampal volume/function and default mode network. In R. McIntyre & D. Cha (Eds.) *Cognitive Dysfunction in Major Depressive Disorder*. Cambridge, UK: Cambridge University Press, 2016.
4. Ketter, TA, **Rasgon, NL**, & Vemuri, M. (2015). Treatment of women with bipolar disorder. In TA Ketter (ed.), *Advances in Treatment of Bipolar Disorders* (pp.199-216). American Psychiatric Publishing: Washington, DC
5. Robakis, TK, & **Rasgon, NL** (2015). Hormonal influences on behavior. Reference Module in Biomedical Sciences. Elsevier Publishing.
6. Robakis TK, & **Rasgon, NL** (2014). Hormonal influences on behavior. In M. Simon & J. Abelson (eds.), *Encyclopedia of Human Biology (3rd edition)*. Elsevier Publishing: Oxford, UK
7. Kenna, H., Ghezelayagh, T., & **Rasgon, N. L.** (2010). The epidemiology of mental disorders in older women. In B.L. Levin & M. Becker (Eds.) Women’s Mental Health Services. Springer; New York, NY.
8. **Rasgon NL**, Hendrick VC, Garrick TR. (2009) Endocrine and metabolic disorders. In BJ Sadock, VA Sadock, P Ruiz (eds): *Kaplan & Sadock's Comprehensive Textbook of Psychiatry (9th ed)*.
9. Powers B, Williams E, Wroolie T, Khaylis A, & **Rasgon, N.L**. Clinical data of estrogen’s effects in the central nervous system: estrogen and mood. In E. Hogervorset, V. Henderson, R. Gibbs, & R. Brinton R. (Eds.): *Hormones, Cognition and Dementia: State of the Art and Emergent Therapeutic Strategies*. Cambridge, UK: Cambridge University Press, 2009.
10. Vemuri, M., Stemmle, P., Jiang, B., Morenkova, A., **Rasgon, N.L**. Insulin Resistance in Bipolar Women: Effects of Mood Stabilizing Drugs. In: B.E. Leonard (Ed.): *Modern Trends in Pharmacopsychiatry*. vol 26. Karger, 2008.
11. Stemmle, P.G., Kenna, H.A., **Rasgon, N.L**. PCOS, Depression and Alzheimer’s Disease. In: N. Fadir (Ed.): *Polycystic Ovary Syndrome*. Springer, 2008.
12. Zappert, L.N., & **Rasgon, N.L.** Management of women with bipolar disorder. In T.A. Ketter (Ed), Clinical Manual of Bipolar Disorder. Washington, DC & London, England: American Psychiatric Publishing, Inc., 2008.
13. Kenna, H., Reynolds, M.F., Jiang, B. & **Rasgon, N.L.** Insulin resistance link between depressive disorders and cognitive dysfunction. In J. Stubenrauch (Ed.) *Metabolic Syndrome and Neuropsychiatric Disorders*, Informa, New York, NY, 2008.
14. **Rasgon NL.** Insulin Resistance and Metabolic Syndrome in Neuropsychiatry. In NL Rasgon (Ed): *Insulin Resistance, Affective Disorders and Alzheimer’s Disease*. Taylor and Francis 2007.
15. **Rasgon NL**, Wroolie TE. Common clinical issues in perimenopause and beyond: Psychological issues*. In Menopause practice: A clinician’s guide (3rd ed.)*. Cleveland, Ohio: The North American Menopause Society, 2007.
16. Reynolds MF, **Rasgon NL**. Obesity, Polycystic Ovary Syndrome, and Mood Disorders. In M. Dekker (Ed): *Obesity and Mental Disorders: Practical and Theoretical Considerations*, 2006.
17. Kenna HA, Reynolds MF, **Rasgon NL**. Insulin Resistance, Depressive Disorders, and Alzheimer’s Disease. In: *Progress in Alzheimer’s Disease Research*. Nova Science Publishers, Inc., 2006.
18. Ernst H, Silverman HS, **Rasgon NL**.  Östrogen und Testosteron. In: Bauer M, Berghöfer A, Adli M (Eds): *Akute und Therapieresistente Depressionen*. Springer, Heidelberg, 2005.
19. **Rasgon NL**, Zappert LN. Special Considerations in Women with Bipolar Disorder. In C. Bowden, J. Calabrese and T. Ketter (Eds): *Advances in Treatment of Bipolar Disorders*. In The American Psychiatric Association Annual Advances in Psychiatry. May 2005.
20. **Rasgon NL**, Hendrick VC, Garrick TR. Endocrine and Metabolic Disorders. In B. Sadock, V. Sadock (Eds): *Comprehensive Textbook of Psychiatry*. Lippincott Williams & Wilkins, 2004.
21. Bauer M, Glenn T, **Rasgon N**, Grof P, Gyulai L, Neuhaus K, Sasse J, Whybrow PC. New Technology for Longitudinal Studies of Patients with Bipolar Disorder. In M. Brown (Ed): *Focus on Bipolar Disorder Research*. Nova Science Publishers Inc, 2004:1-13.
22. **Rasgon, NL**. The North American Menopause Society: *Menopause Core Curriculum Study Guide*. The North American Menopause Society, 2002.
23. **Rasgon NL**, Truong CT. Depression and Dysthymia. In J. Pregler, A. de Cherney (Eds): *Women’s Health: Principles and Clinical Practice*. B.C. Decker Inc, 2002.
24. Driessen N, **Rasgon NL**. Premenstrual Syndrome and Premenstrual Dysphoric Disorder. In J. Pregler, A. de Cherney (Eds): *Women’s Health: Principles and Clinical Practice*. B.C. Decker Inc, 2002.
25. **Rasgon NL**, McGuire MT, Troisi A. Evolutionary Concepts of Gender Differences in Depressive Disorders. In K. Yonkers, M. Steiner (Eds): *Mood Disorders in Women*. Martin Dunitz, 2000.
26. **Rasgon NL**, McGuire MT, Troisi A. Gender and Psychotherapy – An Evolutionary Perspective. In P. Gilbert (Ed): *Genes on the Couch*. 2000.
27. Rapkin AJ, **Rasgon NL**, Berkley KT. Dysmenorrhea. In T. Yaksh (Ed): *Anesthesia, Biologic Foundation*. Raven Press, 1997.

**FUNDING SOURCES AND GRANTS (Current):**

**(Total Direct Costs; NL Rasgon – P.I., unless otherwise indicated)**

1. William Hearst Foundation: “Genetic Biomarkers of Executive Stress”

2015 to Present

Purpose: The purpose of this study is to evaluate the relationship between overall levels of stress and telomere length in individuals who hold executive-level positions.

1. Magceutics, Inc. :“The Use of Magnesium L-Threonate for the Enhancement of Learning and Memory in People with Mild to Moderate Dementia”

2014 to Present

Purpose: The purpose of this study is to examine the effects of supplementing magnesium l-threonate in people with mild to moderate dementia. The goal is to understand whether supplementation is associated with improvement in magnesium deficiency, changes in regional cerebral metabolism, and neurocognitive outcomes.

1. National Institute of Mental Health (NIMH): “Insulin Resistance in Patients With Mood Disorders”

2011 to Present

Purpose: The purpose of this study is to see how insulin sensitizing medication, Pioglitazone, causes changes in mood in some depressed patients. The use of Pioglitazone is considered   
experimental in patients with depression without diabetes.

1. Corcept Pharmaceuticals – “Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance among Older Middle—Aged and Older Individuals”

February 2013 to Present.

Purpose: The purpose of this study is to see how Mifepristone (RU-486), a synthetic steroid medication, can cause changes in cortisol levels (a stress hormone in the body) as well as changes in verbal memory and attention in people with a history of depression.

1. American Diabetes Association (ADA): “Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults with Prediabetes” July 2012 to Present

Purpose: The purpose of this study is to evaluate the effects of liraglutide on the hippocampus and its functional connectivity, and performance on hippocampal mediated cognitive tasks in subjects who are older (50 - 70years of age), overweight/obese and with prediabetes. Half of all subjects will have a family history of Alzheimer's disease, while the other half will be free of such history.

1. Bayer HealthCare Pharmaceutical Inc.: 2/1/2010 - 5/31/2013 “An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ?-amyloid when compared to postmortem histopathology: Safety and efficacy of positron emission tomography imaging with BAY 94-9172 (ZK 6013443)”

Purpose: To the efficacy and safety of a new Bayer imaging compound used in positron emission tomography (PET) imaging for detection/exclusion of cerebral ?-amyloid when compared to postmortem histopathology.

1. American Diabetes Association: 8/1/2010 ­- 7/31/2013

“Behavioral and cognitive correlates of insulin resistance in major depression”

Purpose: To quantify insulin resistance and neuropsychological performance in patients with a recent major depression episode currently in the partial or full remission phase and to examine the potential relationship between severity of insulin resistance and neuropsychological deficits.

1. Stanford Center for Longevity (PI: Ruth O’Hara): "Sleep Apnea and Insulin Resistance: A Role in Cognitive Decline”. 2008-2010, $50,000. Purpose: To evaluate the relationship between normal aging, sleep disordered breathing, genetic factors, and cognition.
2. National Institute of Aging (NIA): “Estrogen Use in Protection from Cognitive Decline.” 2003-2009, $2,490,443. Purpose: To evaluate changes in cerebral metabolism in postmenopausal women at risk for Alzheimer’s Disease.
3. National Institute of Mental Health (NIMH): “Reproductive Endocrine Function and Mood in Women with Bipolar Disorder.” 2004-2009, $1,500,000. Purpose: To expand current knowledge of reproductive biology in women with bipolar disorder as well as assess the impact of current medication status (e.g. intake of mood stabilizers and atypical antipsychotics).
4. GlaxoSmithKline: “Lamotrigine™ in the Treatment of Rapid Cycling Bipolar Disorder in Women of Reproductive Age.” In collaboration with the University of Texas at San Antonio. 2005-2009, $340,000. Purpose: To explore the safety of lamotrigine in treating bipolar disorders in women compared to other mood stabilizers and antidepressants, with regard to the effects on metabolic and reproductive endocrine function as well as mood and menstrual cycle.
5. “Psychotropic Medication Exposure in Premature Infants Admitted to the Neonatal Intensive Care Unit and Special Care Nursery at Stanford University Medical Center” Packard Foundation seed grant 2007-current, $50,000 (Co-P.I.)
6. “Swedish Twin Registry - Depression and Blood Lipids” (in collaboration with Karolinska Institutet and USC; support pending)
7. “Effects of Estrogen Hormone Therapy on Telomere Length” (in collaboration with UCSF; support pending)

**FUNDING SOURCES AND GRANTS (Past):**

1. National Institute of Aging (NIA): "Window of Opportunity of Estrogen Therapy for Neuroprotection", grant # 1R13AG032903, 9/1/09-8/31/10.
2. Window of Opportunity of Estrogen Therapy for Neuroprotection, International Conference, Stanford University, California, 2010. Co-sponsored by Stanford Center for Longevity
3. GlaxoSmithKline: “A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) in subjects with mild-to-moderate Alzheimer's disease (REFLECT-5)” 6/13/2008 -12 /31/20010, $36,324. Purpose: To investigate the effects of rosiglitazone (extended release tablets) as monotherapy on cognition and overall clinical response in subjects with mild to moderate Alzheimer’s disease.
4. GlaxoSmithKline: “A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepizil, and placebo as monotherapy on cognition and overall clinical response in APOE €4-stratified subjects with mild to moderate Alzheimer’s disease (REFECT-1)” 4/23/2007 - 3/31/2009, $87,830. Purpose: To investigate the effects of rosiglitazone (extended release tablets), donepizil, and placebo as monotherapy on cognition and overall clinical response in APOE €4-stratified subjects with mild to moderate Alzheimer’s disease.
5. Wyeth: “A Multicenter, randomized, double-blind placebo-controlled study followed by a 6-month open-label extension to evaluate the efficacy and safety of DVS SR in peri- and postmenopausal women with major depressive disorder” 11/29/06-10/14/08, $160,289. Purpose: To explore the efficacy of desvenlafaxine and to collect safety and tolerability data on subjects during the open-label treatment phase.
6. Forest Laboratories: “Namenda ™ in the Treatment of Women at Risk for Cognitive Decline.” 2005-2008, $180,000. Purpose: To explore the efficacy of Namenda and to monitor neurocognitive functioning in women at risk for cognitive decline.
7. Abbott Laboratories: Depakote ER™ “Study of the Reproductive Function in Women with Bipolar Disorder.” 2003-2005, $68,000. Purpose: To determine the effects of Depakote on reproductive hormone levels throughout the menstrual cycle.
8. Forest Laboratories: Lexapro™ “Escitalopram in the Treatment of Women with Mid-life Depression.” 2003-2005, $98,000. Purpose: To analyze the efficacy of S-Citalopram in the treatment of depression of menopausal women, both estrogen users and nonusers.
9. National Institute of Mental Health (NIMH), FIRST Award: “Estrogen Replacement Therapy, Depression, and Cognition in Postmenopausal Women.” 1998-2003, $350,000. Purpose: To study estrogen replacement therapy’s effect in aging women.
10. UCLA Opportunities Funding: “Magnetic Resonance Spectroscopy across the Menstrual

Cycle in Women with Premenstrual Dysphoric Disorder and Controls.” 1996, $6,000.

Purpose: To study brain neurochemistry across the menstrual cycle: PMDD patients and

controls.

1. Stanley Foundation Research Award: “A Longitudinal Study of the Reproductive Endocrine Function in Women with Bipolar Disorder.” 2000-2002, $75,000.

Purpose: To study the reproductive status in bipolar women.

1. Stanley Bipolar Network: “Cross-Sectional Study of the Medication Status and Polycystic Ovarian Syndrome in Women with Bipolar Disorder.” 1995-2002, $75,000. Purpose: To study reproductive status in women taking mood stabilizers across five sites.
2. Breast Cancer Research Foundation: “Neuroimaging Correlates of Cognitive Dysfunctionafter Breast Cancer Treatment.” (Patti Ganz – P.I.) 2001-2003, $225,000. Purpose: To evaluate cognitive performance in cerebral metabolism among women with breast cancer, survivors and controls.
3. National Institute of Mental Health (NIMH): “Hepatic Encephalopathy: Neuropsychology and Neurochemistry.” (Albert Thomas – P.I.) 1999-2003, $587,747. Purpose: To evaluate absolute metabolite levels, to perform neuropsychological test battery, to record MRI of basal ganglia and to correlate these findings in SHE patients and compare with healthy controls.
4. Thyroid Research Advisory Council (TRAK): “Brain Glucose Metabolism in Hypothyroidism: a Positron Emission Tomography (PET) Study Before and After Treatment.” (Daniel Silverman – P.I.) 1999-2003, $74,196. Purpose: To evaluate effects of hypothyroidism, as well as of hormone replacement therapy with levothyroxine, on brain function.
5. National Alliance for Research on Schizophrenia and Depression (NARSAD): “Effects of TSH-Suppressive Levothyroxine on Cerebral Activity and Hypothalamic-Pituitary Systems in Female Bipolar Disorders.” (Michael Bauer – P.I.) 1999-2002,$50,000. Purpose: To investigate the effects of thyroid replacement on the neuroendocrine system in women with bipolar disorder.
6. UCLA Opportunities Funding: “Reproduction and Social Stress-Related Changes in Female Vervet Monkeys.” 1998, $2,000. Purpose: To establish neuroendocrine alterations following change in rank of female vervet monkeys.
7. Forest Laboratories: “Study of the Effects of Estrogen Replacement Therapy on the Course of Depression and Cognition in Perimenopausal Women.” 2001-2002, $55,000. Purpose: To study the effects of estrogen replacement therapy on antidepressant response in a double-blind, placebo controlled paradigm.
8. Forest Laboratories: “Flexible Dose Comparison of the Safety and Efficacy of LU-26-054, Citalopram and Placebo in the Treatment of Major Depressive Disorder.” 1999, $140,000. Purpose: To study the safety and efficacy of a novel antidepressant.
9. Solvay Pharmaceuticals: Unrestricted Research Grant. 1997, $25,000. Purpose: To study the effects of estrogen replacement therapy in the treatment of depression and anxiety in the perimenopausal woman.

**PATENTS:**

1. Bakultteva LP, **Luzina NL**, Basina ZA: Method of Dysmenorrhea Treatment, Certificate of New Technology Proposal #91/87, 1987.
2. **Luzina NL**, Tjagai OJ: Improved Method of Mitochondrial Destruction. Certificate of Technology Proposal #600, 1977.
3. **Luzina NL**, Zelinski AA, Nicushkin EV, Kryzhanovskii GN: Substance for the Reduction of Side Effects During Physical Medicine Treatment. Invention, Priority 1985, Certificate 1989.
4. **Luzina NL**, Nichushkin EV, Kryzhanovskii: Method of Dysmenorrhea Treatment. Invention, Priority 1985, Certificate 1989.

**EXPERIENCE AS FACULTY RESEARCH MENTOR:**

1. Alice Ely, Wismer Scholar & Postdoctoral Fellow, UCSD Eating Disorders Center, 2015-present
2. Emily Goard Jacobs, PhD, Department of Psychiatry, Harvard Medical School, 2013-present
3. Rodrigo Mansur, MD, Fellow, University of Toronto, 2013-present
4. Dorota Lojko, MD, PhD, University of Medical Sciences, Poznan, Poland 2013-present
5. Marisa Spann, Columbia University, 2013-present
6. Thalia Robakis, MD, PhD, Clinical Assistant Professor, Stanford University, 2011-present
7. Donna Roybal, MD, University of Texas Health Sciences Center at San Antonio, 2009-present
8. Jacob Ballon, MD, Assistant Professor of Psychiatry, Stanford University, 2009-present
9. Ariadna Forray, MD, Assistant Professor of Psychiatry, Yale School of Medicine, 2013-present
10. Amanda Bischoff-Grethe, MD, Assistant Adjunct Professor, University of California, San Diego
11. Anna Morenkova, MD PhD, Chief Neurology Resident
12. Violetta Tan, M.D., resident, 2009 -present
13. Rania Awaad, resident, PGY-2, 2007 to present
14. Mytilee Vemuri, M.D., T-32 fellow, 2006 –present
15. Deborah Flores, M.D., NRSA Research fellow, 2002- present
16. Hugh Brent Solvason, M.D., Ph.D., NARSAD Junior Investigator Award, 2005- 2007
17. Amanda Templeton, M.D., resident, and research physician, 2004-2008
18. Kirti Saxena, M.D., fellow, 2004- 2006
19. Wendy Marsh, M.D., resident and T-32 fellow, 2003- 2007
20. Heidi Ernst, 4th year resident and fellow 2003-2004
21. Mollie Carter, 1st year medical student, 2001- 2002
22. Ying Wang, 1st year medical student, UCLA, 2001
23. Shana Elman, M.D. GI Fellow, Southwestern University, 2000-present
24. Carolyn Lu, 1st year medical student, 1999- 2002
25. Rehka Rao, M.D., 1999-2002
26. Co Truong, 1st year medical student, 1998- 2001
27. Martha Love, M.D., 1998-2003
28. Karen Miller, Ph.D., Postdoctoral Fellow in Geriatrics, 1998-2001

**UNDERGRADUATE RESEARCH TRAINEES:**

1. Jessie Holtzman, undergraduate student, Honors Thesis, 2012-present
2. Nicky Gumport, undergraduate student, research trainee, 2012-present
3. Maile Jones, undergraduate student, Tulane University, 2015-2016
4. Siena Roat-Shumway, undergraduate student, UCLA, 2015-2016
5. Abigail Faisal, undergraduate student, undergraduate student, University of California, Davis, 2014-2015
6. Lindsey Negrete, undergraduate, Stanford University, 2009 to 2013
7. Paula de los Angeles, undergraduate, Stanford University, 2009 to 2013
8. Robert Watkins, undergraduate, Stanford University, 2009 to 2013
9. Daniel Graham, undergraduate, Stanford University, 2009 to 2013
10. Sara Silberstein, undergraduate, Stanford University, 2009 to 2013
11. Elizabeth Wendel, undergraduate, Stanford University, 2009 to 2013
12. Elizabeth Heimbaugh, undergraduate, Stanford University, 2009 to 2013
13. Suzan Ahmed, undergraduate, Stanford University, 2009
14. Lauren Hofmayer, undergraduate, Stanford University, 2008 to 2009
15. Meredith Ayers, undergraduate, Honors Thesis, Stanford University, 2008 to 2012
16. Deborah Akinny, undergraduate, Stanford University, 2008 to 2009
17. Molly Tartter, undergraduate, Honors Thesis, Stanford University, 2007 to 2008
18. Kathleen Wong, undergraduate, Honors Thesis, Stanford University, 2007 to 2008
19. Quynh Nguyen, undergraduate, Stanford University, 2007 to 2008
20. Bowen Jiang, undergraduate, Stanford University, 2007- 2008
21. Anna Khaylis, graduate student, PGSP-Stanford Ph.D., 2007 to 2008
22. Ari Dubin, undergraduate, Wellesley College, Summer 2007
23. Nick Noone, undergraduate, Stanford University, 2006 to 2007
24. Megan Holcomb, graduate student, PGSP-Stanford Ph.D., 2006 to 2009
25. Taylor Cox, undergraduate, Stanford University, 2006 to present
26. Jennifer Tangtiphaiboontana, undergraduate, Stanford University, 2006
27. Talayeh Ghezelayagh, undergraduate, Stanford University, 2006 to 2008
28. Eileen Sisk, undergraduate, Stanford University, 2006
29. Matt Anderson, undergraduate, Stanford University, Fall 2006
30. Shawn Kann, undergraduate, Stanford University, 2005- 2006
31. Celi Herrera, undergraduate, Stanford University, 2005-2006
32. Karina Salizar, undergraduate, Stanford University, Spring 2005
33. Sharareh Saadat, undergraduate, UCLA Student Research Program, 2001-2005
34. Kai Truong, Student Research Program, 1997-2000
35. Corina Wang, Student Research Program, 1997-2000

**MENTOR FOR GRADUATE STUDENTS**

1. Itzel Anaya, graduate student, Palo Alto University, 2015-present
2. Jessica Watson, graduate student, Palo Alto University, 2015-present
3. Xuan Duong, graduate student, Palo Alto University, 2015-present
4. Abigail Kramer, graduate student, Palo Alto University, 2015-present
5. Katie Watson-Lin, Ph.D. student in Epidemiology, Stanford University, 2013-present
6. Chelsea Tobin, graduate student, Palo Alto University, 2015-2016
7. Nikki Stoddart, graduate student, Master in Epidemiology, Stanford University, 2007
8. Laurel Zappert, graduate student, PGSP-Stanford Psy. D., 2002-2008
9. Kristen Leight, MA, 1999-2001
10. Sohrab Tanavoli, graduate student, Master of Science, 1997-2000
11. Lara Pamfrey, graduate student, UCLA School of Physiology, 1995-1997

**MENTOR FOR GRADUATE STUDENTS IN NEUROSCIENCE IN WOMEN’S HEALTH PROGRAM**

1. Claire Clark, PhD Graduate Student, Palo Alto University, Fall 2012 to Present
2. Sarah Borish, PhD Graduate Student, Palo Alto University, Fall 2012 to Present
3. Vena Budhan, PhD Graduate Student, Palo Alto University, Fall 2012 to Present
4. Christine Earle, PhD Graduate Student, Palo Alto University, 2011 to Present
5. Danielle Balzafiore, PhD Graduate Student, Palo Alto University, 2011 to Present
6. Diandra Hilton, PhD Graduate Student, Palo Alto University, 2011 to Present
7. Iulia Ivan, PhD Graduate Student, Palo Alto University, 2011 to Present
8. Lisa Hoyman, PhD Graduate Student, Palo Alto University, 2011 to Present
9. Anna Staudenmeyer, PhD Graduate Student, Palo Alto University, 2011 to Present
10. Erin Moniz, PhD Graduate Student, Palo Alto University, 2011 to 2016
11. Jennifer Zahm, PhD Graduate Student, Palo Alto University, 2011 to 2016
12. Elizabeth Peters, PhD Graduate Student, Palo Alto University, 2011 to 2016
13. Josh Tal, PhD Graduate Student, Palo Alto University, 2011 to 2016
14. Brooke Collins, PhD Graduate Student, Palo Alto University, 2010 to 2016
15. Heather Kenna, PhD Graduate Student, Palo Alto University, 2009 to 2016
16. Meagan Stanley, PhD Graduate Student, Palo Alto University, Fall 2012 to 2015
17. Anna Zozulinsky, PhD Graduate Student, Palo Alto University, 2010 to 2015
18. Jade Garneau-Fournier, PhD Graduate Student, Palo Alto University, 2010 to 2015
19. Jamie Gannon, PhD Graduate Student, Palo Alto University, 2010 to 2015
20. Tara Emrani, PhD Graduate Student, Palo Alto University, 2010 to 2015
21. Ann Bilbrey,PhD Graduate Student, Palo Alto University, 2009 to 2014
22. Cere Fingerhut,PhD Graduate Student, Palo Alto University, 2009 to 2014
23. Venus Mahmoodi, PhD Graduate Student, Palo Alto University, 2010 to 2014
24. Daniele Levy, PhD Graduate Student, Palo Alto University, 2009 to 2013
25. Debbie McDivitt, PhD Graduate Student, Palo Alto University, 2009 to 2013
26. Johanna Rengifo-Nevarez, PhD Graduate Student, Palo Alto University, 2009 to 2013
27. Aleksandra Stepanenko, PhD Graduate Student, Palo Alto University, 2009 to 2013

**RESEARCH AFFILIATIONS:**

1. Clayman Institute for Gender Research, Stanford University, 2010 to Present
2. Center for Longevity, Stanford University, 2008 to Present
3. Neuroscience Institute at Stanford, 2007 to Present
4. Sysematic Treatment Enhancement Program for Bipolar Disorder (Step-BP),Stanford University School of Medicine, 2003-2007
5. Women’s Health Initiative (WHI-WHIMS), 1998-2000
6. Stanley Research Foundation, 1995-2002
7. Center on Aging, University of California, Los Angeles, 1995-2002
8. Center for Primate Neuroethology, University of California, Los Angeles, 1995 TO 2002

**RESEARCH COLLABORATIONS (current):**

1. PALS (Founder), International Research Collaborative Network, Stanford Center for Neuroscience in Women’s Health and Stanford Center for Mood Disorders; Center for Neuropsychopharmacology, University of Toronto, Canada; Rockefeller University; Icahn School of Medicine at Mt. Sinai; Erasmus University, Rotterdam, The Netherlands; University of South Carolina
2. PACT Consortium (Postpartum Depression ACT), University of North Carolina at Chapel Hill
3. Palo Alto Medical Foundation Research Institute
4. University of Toronto, Canada, Psychiatry and Pharmacology Program
5. University of California at San Francisco, Department of Psychiatry
6. Stanford Cardiovascular Institute
7. University of Dresden, Department of Psychiatry
8. University of Cagliari, Department of Pharmacology, Italy
9. University of Washington School of Medicine, Department of Psychiatry and Behavioral Sciences, Seattle
10. Veterans Affairs Puget Sound Health Care System, Seattle
11. University of California at Los Angeles, Department of Nuclear Medicine, Crumps Institute of Pharmacology
12. University of California, Department of Obstetrics and Gynecology
13. Swedish Twin Registry, Karolinska Institutet
14. University of Southern California

**RESEARCH COLLABORATIONS (past):**

1. Department of Psychiatry, Bipolar Clinic, Catholic University, Chile
2. University of California at Los Angeles, Brain Mapping Center
3. University of California at Los Angeles, Department of Internal Medicine, Division of Endocrinology
4. University of California, Breast Cancer Center
5. Humboldt University of Berlin, Germany
6. University of Texas San Antonio